

Mikkael A Sekeres

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8143226/mikkael-a-sekeres-publications-by-citations.pdf>

Version: 2024-04-18

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

1,016
papers

19,984
citations

68
h-index

127
g-index

1,056
ext. papers

24,375
ext. citations

3.8
avg, IF

6.44
L-index

#	Paper	IF	Citations
1016	Revised international prognostic scoring system for myelodysplastic syndromes. <i>Blood</i> , 2012 , 120, 2454-65	6.5	1799
1015	Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. <i>Blood</i> , 2015 , 126, 9-16	2.2	1005
1014	Enasidenib in mutant relapsed or refractory acute myeloid leukemia. <i>Blood</i> , 2017 , 130, 722-731	2.2	831
1013	Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. <i>New England Journal of Medicine</i> , 2018 , 378, 2386-2398	59.2	708
1012	Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. <i>Blood</i> , 2009 , 113, 1315-25	25	336
1011	Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. <i>Annals of Oncology</i> , 2020 , 31, 745-759	10.3	303
1010	Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. <i>Blood</i> , 2012 , 119, 3203-10	2.2	293
1009	STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. <i>Blood</i> , 2012 , 120, 3048-57	2.2	285
1008	Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. <i>Blood</i> , 2008 , 111, 1534-42	2.2	281
1007	Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. <i>Blood</i> , 2011 , 118, 3932-41	2.2	265
1006	250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. <i>Cancer Research</i> , 2008 , 68, 10349-57	10.1	257
1005	Dynamics of clonal evolution in myelodysplastic syndromes. <i>Nature Genetics</i> , 2017 , 49, 204-212	36.3	228
1004	Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms. <i>Cancer Cell</i> , 2015 , 27, 658-70	24.3	228
1003	Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. <i>Leukemia</i> , 2014 , 28, 78-87	10.7	226
1002	Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. <i>Journal of the National Cancer Institute</i> , 2008 , 100, 1542-51	9.7	209
1001	Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. <i>Blood</i> , 2017 , 129, 2347-2358	2.2	184
1000	Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. <i>Journal of Clinical Oncology</i> , 2009 , 27, 6109-16	2.2	183

999	The incidence and impact of thrombocytopenia in myelodysplastic syndromes. <i>Cancer</i> , 2007 , 109, 1705-1714	10.4	179
998	Somatic SETBP1 mutations in myeloid malignancies. <i>Nature Genetics</i> , 2013 , 45, 942-6	36.3	178
997	SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. <i>Leukemia</i> , 2012 , 26, 542-5	10.7	178
996	Molecular remission and response patterns in patients with mutant- acute myeloid leukemia treated with enasidenib. <i>Blood</i> , 2019 , 133, 676-687	2.2	178
995	Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. <i>Blood</i> , 2006 , 108, 2173-81	2.2	168
994	Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. <i>Blood</i> , 2011 , 117, 4552-60	2.2	167
993	Acute myeloid leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2004 , 2004, 98-117	3.1	164
992	Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. <i>Blood</i> , 2009 , 113, 28-36	2.2	162
991	Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. <i>Leukemia</i> , 2004 , 18, 809-16	10.7	160
990	Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. <i>New England Journal of Medicine</i> , 2020 , 382, 140-151	59.2	160
989	Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2745-2753	2.2	154
988	Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. <i>Journal of Clinical Oncology</i> , 2010 , 28, 437-44	2.2	154
987	SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. <i>Blood</i> , 2012 , 120, 3173-86	2.2	152
986	Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies. <i>Leukemia</i> , 2010 , 24, 1799-804	10.7	152
985	Genetic alterations of the cohesin complex genes in myeloid malignancies. <i>Blood</i> , 2014 , 124, 1790-8	2.2	151
984	Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms. <i>Blood</i> , 2013 , 122, 999-1006	10.6	122
983	Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2253-8	2.2	113
982	Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , 2016 , 17, 496-508	21.7	112

981	Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. <i>Cancer</i> , 2014 , 120, 1838-46	6.4	107
980	In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. <i>Mayo Clinic Proceedings</i> , 2015 , 90, 996-1000	6.4	105
979	Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies. <i>Leukemia</i> , 2013 , 27, 1301-9	10.7	105
978	Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. <i>Blood</i> , 2012 , 120, 4945-51	2.2	105
977	Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. <i>Blood</i> , 2017 , 130, 1514-1522	2.2	102
976	New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5219-26	2.2	99
975	Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes. <i>Leukemia</i> , 2016 , 30, 2214-2220	10.7	98
974	Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy. <i>Clinical Cancer Research</i> , 2013 , 19, 938-48	12.9	96
973	Time-dependent changes in mortality and transformation risk in MDS. <i>Blood</i> , 2016 , 128, 902-10	2.2	93
972	Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5943-9	2.2	92
971	Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine. <i>Leukemia Research</i> , 2013 , 37, 609-13	2.7	90
970	Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study. <i>Leukemia</i> , 2012 , 26, 1286-92	10.7	90
969	An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. <i>Blood Cancer Journal</i> , 2015 , 5, e333	7	89
968	Eprenetapopt (APR-246) and Azacitidine in -Mutant Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1584-1594	2.2	89
967	SNP array-based karyotyping: differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromes. <i>Blood</i> , 2011 , 117, 6876-84	2.2	88
966	TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. <i>Leukemia</i> , 2019 , 33, 1747-1758	10.7	88
965	Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis. <i>Blood</i> , 2012 , 119, 6109-17	2.2	87
964	Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis. <i>PLoS ONE</i> , 2012 , 7, e43090	3.7	85

963	Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. <i>Blood</i> , 2004 , 103, 4036-42	2.2	82
962	Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia. <i>Haematologica</i> , 2011 , 96, 1269-75	6.6	81
961	How we treat higher-risk myelodysplastic syndromes. <i>Blood</i> , 2014 , 123, 829-36	2.2	80
960	Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1047-53 ²	2.2	80
959	Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1343-9	2.2	79
958	Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality. <i>JAMA Oncology</i> , 2017 , 3, 1675-1682	13.4	78
957	The epidemiology of myelodysplastic syndromes. <i>Hematology/Oncology Clinics of North America</i> , 2010 , 24, 287-94	3.1	78
956	Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium. <i>Cancer</i> , 2015 , 121, 876-82	6.4	76
955	Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial. <i>Lancet Haematology</i> , 2018 , 5, e63-e72	14.6	76
954	Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM). <i>Leukemia</i> , 2015 , 29, 1502-13	10.7	76
953	Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results. <i>American Journal of Hematology</i> , 2018 , 93, 1301-1310	7.1	75
952	Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee. <i>Blood</i> , 2015 , 126, 907-907	2.2	73
951	Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. <i>Blood Advances</i> , 2018 , 2, 923-932	7.8	73
950	SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. <i>Blood</i> , 2020 , 136, 157-170	2.2	72
949	A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605. <i>Blood</i> , 2011 , 118, 523-8	2.2	69
948	Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes. <i>Cancer</i> , 2017 , 123, 994-1002	6.4	68
947	Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion. <i>Oncogene</i> , 2013 , 32, 1110-20	9.2	68
946	Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia. <i>Haematologica</i> , 2013 , 98, 119-28	6.6	68

945	Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1831-1839	2.2	67
944	Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS. <i>Leukemia</i> , 2014 , 28, 1033-40	10.7	66
943	Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome. <i>Journal of Immunology</i> , 2012 , 189, 3198-208	5.3	66
942	Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2008 , 142, 379-93	4.5	66
941	Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub. <i>Blood Advances</i> , 2020 , 4, 5966-5975	7.8	66
940	A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML). <i>Clinical Cancer Research</i> , 2016 , 22, 3746-54	12.9	65
939	Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia. <i>Haematologica</i> , 2013 , 98, 107-13	6.6	65
938	Daptomycin-resistant <i>Enterococcus faecium</i> in a patient with acute myeloid leukemia. <i>Mayo Clinic Proceedings</i> , 2005 , 80, 1215-6	6.4	65
937	Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2007 , 137, 125-32	4.5	63
936	The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. <i>Blood Advances</i> , 2018 , 2, 1765-1772	7.8	63
935	Genomic determinants of chronic myelomonocytic leukemia. <i>Leukemia</i> , 2017 , 31, 2815-2823	10.7	61
934	Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes. <i>Journal of Clinical Investigation</i> , 2015 , 125, 1043-55	15.9	60
933	Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. <i>Cancer</i> , 2011 , 117, 992-1000	6.4	58
932	Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms. <i>Leukemia</i> , 2015 , 29, 2134-42	10.7	57
931	p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia. <i>Leukemia</i> , 2011 , 25, 1739-50	10.7	57
930	Epidemiology, natural history, and practice patterns of patients with myelodysplastic syndromes in 2010. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011 , 9, 57-63	7.3	57
929	FISH and SNP-A karyotyping in myelodysplastic syndromes: improving cytogenetic detection of del(5q), monosomy 7, del(7q), trisomy 8 and del(20q). <i>Leukemia Research</i> , 2010 , 34, 447-53	2.7	56
928	Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1591-1597	2.2	55

927	Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial. <i>Blood</i> , 2015 , 126, 323-323	2.2	55
926	An assessment of the usefulness of the Duke criteria for diagnosing active infective endocarditis. <i>Clinical Infectious Diseases</i> , 1997 , 24, 1185-90	11.6	54
925	Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors. <i>Clinical Cancer Research</i> , 2018 , 24, 1705-1715	12.9	53
924	Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. <i>Lancet Haematology</i> , 2018 , 5, e117-e126	14.6	52
923	Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1252-7	2.2	51
922	Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012 , 53, 417-23	1.9	51
921	Risk factors for clinically important adverse events after protamine administration following cardiopulmonary bypass. <i>Journal of the American College of Cardiology</i> , 1998 , 32, 1916-22	15.1	49
920	Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019 , 134, 676-676	2.2	48
919	Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides. <i>Leukemia</i> , 2016 , 30, 649-57	10.7	47
918	Detection of cryptic chromosomal lesions including acquired segmental uniparental disomy in advanced and low-risk myelodysplastic syndromes. <i>Experimental Hematology</i> , 2007 , 35, 1728-38	3.1	47
917	Mortality and adverse events after protamine administration in patients undergoing cardiopulmonary bypass. <i>Anesthesia and Analgesia</i> , 2002 , 94, 1402-8, table of contents	3.9	46
916	American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. <i>Blood Advances</i> , 2020 , 4, 3528-3549	7.8	46
915	A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ≥30% blasts. <i>Leukemia</i> , 2017 , 31, 2799-2806	10.7	44
914	Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation. <i>Leukemia</i> , 2016 , 30, 285-94	10.7	44
913	Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013 , 13, 559-67	2	44
912	Smoking and alcohol intake as risk factors for myelodysplastic syndromes (MDS). <i>Leukemia Research</i> , 2010 , 34, 1-5	2.7	44
911	Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL). <i>Leukemia and Lymphoma</i> , 2018 , 59, 416-422	1.9	42
910	p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies. <i>Seminars in Oncology</i> , 2012 , 39, 97-108	5.5	42

909	Novel recurrent mutations in the RAS-like GTP-binding gene RIT1 in myeloid malignancies. <i>Leukemia</i> , 2013 , 27, 1943-6	10.7	42
908	Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes. <i>Leukemia</i> , 2017 , 31, 2848-2850	10.7	41
907	Perceptions of disease state, treatment outcomes, and prognosis among patients with myelodysplastic syndromes: results from an internet-based survey. <i>Oncologist</i> , 2011 , 16, 904-11	5.7	41
906	The challenge of acute myeloid leukemia in older patients. <i>Current Opinion in Oncology</i> , 2002 , 14, 24-30	4.2	41
905	Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. <i>Lancet Haematology</i> , 2020 , 7, e601-e612	14.6	41
904	Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. <i>Lancet Haematology</i> , 2020 , 7, e309-e319	14.6	40
903	Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2011 , 86, 102-3	7.1	40
902	Adverse events after protamine administration in patients undergoing cardiopulmonary bypass: risks and predictors of under-reporting. <i>Journal of Clinical Epidemiology</i> , 1998 , 51, 1-10	5.7	40
901	Enasidenib (AG-221), a Potent Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 (IDH2) Enzyme, Induces Hematologic Responses in Patients with Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2016 , 128, 343-343	2.2	39
900	mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. <i>Blood Advances</i> , 2019 , 3, 922-933	7.8	39
899	Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials. <i>Blood</i> , 2019 , 133, 1020-1030	2.2	39
898	Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron. <i>Leukemia</i> , 2015 , 29, 188-95	10.7	37
897	Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis. <i>Leukemia</i> , 2014 , 28, 1486-93	10.7	37
896	Treatment of older adults with acute myeloid leukemia: state of the art and current perspectives. <i>Haematologica</i> , 2008 , 93, 1769-72	6.6	37
895	Phase 1b/2 Combination Study of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). <i>Blood</i> , 2018 , 132, 3091-3091	2.2	36
894	Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium. <i>Leukemia</i> , 2017 , 31, 1391-1397	10.7	35
893	Recurrent genetic defects on chromosome 7q in myeloid neoplasms. <i>Leukemia</i> , 2014 , 28, 1348-51	10.7	35
892	A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome. <i>Cancer</i> , 2012 , 118, 2138-47	6.4	35

891	Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations. <i>Leukemia Research</i> , 2010 , 34, 969-73	2.7	35
890	Hemochromatosis-associated gene mutations in patients with myelodysplastic syndromes with refractory anemia with ringed sideroblasts. <i>American Journal of Hematology</i> , 2007 , 82, 1076-9	7.1	35
889	Reducing Time to Antibiotic Administration for Febrile Neutropenia in the Emergency Department. <i>Journal of Oncology Practice</i> , 2015 , 11, 450-5	3.1	34
888	SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016 , 128, 901-901	2.2	33
887	Sharing Data from Cardiovascular Clinical Trials--A Proposal. <i>New England Journal of Medicine</i> , 2016 , 375, 407-9	59.2	33
886	Origins of myelodysplastic syndromes after aplastic anemia. <i>Blood</i> , 2017 , 130, 1953-1957	2.2	32
885	The impact of a physician awareness group and the first year of training on hematology-oncology fellows. <i>Journal of Clinical Oncology</i> , 2003 , 21, 3676-82	2.2	32
884	SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2014 , 167, 233-7	4.5	31
883	Outcomes in obese and overweight acute myeloid leukemia patients receiving chemotherapy dosed according to actual body weight. <i>American Journal of Hematology</i> , 2013 , 88, 906-9	7.1	31
882	Impact of remission induction chemotherapy on survival in older adults with acute myeloid leukemia. <i>Cancer</i> , 2007 , 110, 1752-9	6.4	31
881	Single nucleotide polymorphism arrays complement metaphase cytogenetics in detection of new chromosomal lesions in MDS. <i>Leukemia</i> , 2007 , 21, 2058-61	10.7	31
880	The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure. <i>Haematologica</i> , 2016 , 101, e224-7	6.6	30
879	The NEDD8-activating enzyme inhibitor MLN4924 disrupts nucleotide metabolism and augments the efficacy of cytarabine. <i>Clinical Cancer Research</i> , 2015 , 21, 439-47	12.9	30
878	Defining incidence, risk factors, and impact on survival of central line-associated blood stream infections following hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 720-4	4.7	30
877	Consequences of mutant TET2 on clonality and subclonal hierarchy. <i>Leukemia</i> , 2018 , 32, 1751-1761	10.7	30
876	A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction. <i>Haematologica</i> , 2014 , 99, 1176-83	6.6	29
875	The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions. <i>Blood</i> , 2018 , 132, 1-1	2.2	29
874	Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromes. <i>Nature Communications</i> , 2019 , 10, 5386	17.4	29

873	Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy. <i>British Journal of Haematology</i> , 2017 , 178, 906-913	4.5	28
872	Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodysplastic syndromes. <i>Cancer</i> , 2014 , 120, 1670-6	6.4	28
871	Myelodysplastic syndromes: a practical approach to diagnosis and treatment. <i>Cleveland Clinic Journal of Medicine</i> , 2010 , 77, 37-44	2.8	28
870	High-resolution genomic arrays facilitate detection of novel cryptic chromosomal lesions in myelodysplastic syndromes. <i>Experimental Hematology</i> , 2007 , 35, 240-51	3.1	28
869	Increased C-kit intensity is a poor prognostic factor for progression-free and overall survival in patients with newly diagnosed AML. <i>Leukemia Research</i> , 2008 , 32, 913-8	2.7	28
868	Mortality and Adverse Events After Protamine Administration in Patients Undergoing Cardiopulmonary Bypass. <i>Anesthesia and Analgesia</i> , 2002 , 94, 1402-1408	3.9	28
867	Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials. <i>Future Oncology</i> , 2019 , 15, 3531-3545	3.6	27
866	Boulevard of broken dreams: drug approval for older adults with acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4061-3	2.2	27
865	A Decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes. <i>Cancer</i> , 2007 , 109, 1125-32	6.4	27
864	Survival and predictors of outcome in patients with acute leukemia admitted to the intensive care unit. <i>Cancer</i> , 2008 , 112, 2233-40	6.4	27
863	Patients with myelodysplastic syndromes treated with azacitidine in clinical practice: the AVIDA registry. <i>Leukemia and Lymphoma</i> , 2015 , 56, 887-95	1.9	26
862	A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials. <i>Cancer</i> , 2017 , 123, 3662-3672	6.4	26
861	Randomized, dose-escalation study of the p38MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome. <i>Leukemia</i> , 2013 , 27, 977-80	10.7	26
860	A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia. <i>Cancer</i> , 2011 , 117, 1253-61	6.4	26
859	Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable. <i>Blood</i> , 2018 , 132, 2100-2103	2.2	26
858	Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes. <i>Blood</i> , 2016 , 128, 2096-2097	2.2	25
857	Development of a modified surveillance definition of central line-associated bloodstream infections for patients with hematologic malignancies. <i>Infection Control and Hospital Epidemiology</i> , 2012 , 33, 865-8	2	25
856	Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML. <i>Leukemia</i> , 2021 , 35, 2119-2124	10.7	25

855	Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. <i>Leukemia Research</i> , 2018 , 74, 130-136	2.7	24
854	Febrile neutropenia in hematologic malignancies. <i>Current Hematologic Malignancy Reports</i> , 2013 , 8, 370-8	4.4	24
853	Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2012 , 158, 581-8	4.5	24
852	Impact of socioeconomic status and distance from treatment center on survival in patients receiving remission induction therapy for newly diagnosed acute myeloid leukemia. <i>Leukemia Research</i> , 2008 , 32, 413-20	2.7	24
851	Recurrent genetic defects on chromosome 5q in myeloid neoplasms. <i>Oncotarget</i> , 2017 , 8, 6483-6495	3.3	24
850	Germline loss-of-function and alterations in adult myelodysplastic syndromes. <i>Blood</i> , 2018 , 132, 2309-2313	3.3	23
849	PDGFRB-rearranged T-lymphoblastic leukemia/lymphoma occurring with myeloid neoplasms: the missing link supporting a stem cell origin. <i>Haematologica</i> , 2014 , 99, e148-51	6.6	22
848	A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF). <i>Cancer</i> , 2012 , 118, 3968-76	6.4	22
847	Management of lower-risk myelodysplastic syndromes: the art and evidence. <i>Current Hematologic Malignancy Reports</i> , 2011 , 6, 145-53	4.4	22
846	Phase 1/2 Study of AMG 531 in Thrombocytopenic Patients (pts) with Low-Risk Myelodysplastic Syndrome (MDS): Update Including Extended Treatment.. <i>Blood</i> , 2007 , 110, 250-250	2.2	22
845	Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia. <i>Blood Advances</i> , 2018 , 2, 2063-2071	7.8	22
844	A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2017 , 92, 660-667	7.1	21
843	Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1. <i>Blood Cancer Journal</i> , 2018 , 8, 4	7	21
842	Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents. <i>Leukemia Research</i> , 2016 , 41, 43-7	2.7	21
841	Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?. <i>American Journal of Hematology</i> , 2015 , 90, 1036-40	7.1	21
840	Predictive factors for latency period and a prognostic model for survival in patients with therapy-related acute myeloid leukemia. <i>American Journal of Hematology</i> , 2014 , 89, 168-73	7.1	21
839	Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2012 , 87, 957-60	7.1	21
838	Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes. <i>Blood</i> , 2020 , 136, 2249-2262	2.2	21

837	The novel autophagy inhibitor ROC-325 augments the antileukemic activity of azacitidine. <i>Leukemia</i> , 2019 , 33, 2971-2974	10.7	20
836	Combination strategies in myelodysplastic syndromes. <i>International Journal of Hematology</i> , 2012 , 95, 26-33	2.3	20
835	Effect of prior rituximab on high-dose therapy and autologous stem cell transplantation in follicular lymphoma. <i>Bone Marrow Transplantation</i> , 2007 , 40, 973-8	4.4	20
834	Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine. <i>Leukemia</i> , 2018 , 32, 952-959	10.7	20
833	A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2019 , 25, 4231-4237	12.9	19
832	The Revised International Prognostic Scoring System (IPSS-R) is not predictive of survival in patients with secondary myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2015 , 56, 3437-9	1.9	19
831	Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. <i>Leukemia</i> , 2020 , 34, 3149-3160	10.7	19
830	Complete mutational spectrum of the autophagy interactome: a novel class of tumor suppressor genes in myeloid neoplasms. <i>Leukemia</i> , 2017 , 31, 505-510	10.7	19
829	Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q). <i>Blood Cancer Journal</i> , 2014 , 4, e242	7	19
828	Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2019 , 134, 678-678	2.2	19
827	Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?. <i>Oncologist</i> , 2015 , 20, 1069-76	5.7	18
826	Germ line tissues for optimal detection of somatic variants in myelodysplastic syndromes. <i>Blood</i> , 2018 , 131, 2402-2405	2.2	18
825	Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, e463-e468	2	18
824	Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R. <i>American Journal of Hematology</i> , 2018 , 93, 1245-1253	7.1	18
823	Multicenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic cell transplant to hypomethylating therapy or best supportive care in patients aged 50 to 75 with intermediate-2 and high-risk myelodysplastic syndrome: Blood and Marrow Transplant Clinical Trials Network #1102 study rationale, design, and methods. <i>Biology of Blood and Marrow</i>	4.7	18
822	Genomic patterns associated with hypoplastic compared to hyperplastic myelodysplastic syndromes. <i>Haematologica</i> , 2015 , 100, e434-7	6.6	18
821	Ruxolitinib in combination with DNA methyltransferase inhibitors: clinical responses in patients with symptomatic myelofibrosis with cytopenias and elevated blast(s) counts. <i>Leukemia and Lymphoma</i> , 2015 , 56, 497-9	1.9	18
820	Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS). <i>Journal of Hematology and Oncology</i> , 2012 , 5, 18	22.4	18

819	Histone H4 acetylation by immunohistochemistry and prognosis in newly diagnosed adult acute lymphoblastic leukemia (ALL) patients. <i>BMC Cancer</i> , 2010 , 10, 387	4.8	18
818	Thalidomide use and digital gangrene. <i>Journal of Clinical Oncology</i> , 2006 , 24, 5328	2.2	18
817	A Personalized Prediction Model to Risk Stratify Patients with Myelodysplastic Syndromes. <i>Blood</i> , 2018 , 132, 793-793	2.2	18
816	An Open-Label, Phase 2, Dose-Finding Study of Sotatercept (ACE-011) in Patients with Low or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndromes (MDS) or Non-Proliferative Chronic Myelomonocytic Leukemia (CMML) and Anemia Requiring Transfusion. <i>Blood</i> , 2014 , 124, 3251-3251	2.2	18
815	A Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117. <i>Blood</i> , 2014 , 124, LBA-5-LBA-5	2.2	18
814	Severe megaloblastic anemia: Vitamin deficiency and other causes. <i>Cleveland Clinic Journal of Medicine</i> , 2020 , 87, 153-164	2.8	18
813	Invariant phenotype and molecular association of biallelic mutant myeloid neoplasia. <i>Blood Advances</i> , 2019 , 3, 339-349	7.8	18
812	The challenging world of cytopenias: distinguishing myelodysplastic syndromes from other disorders of marrow failure. <i>Oncologist</i> , 2014 , 19, 735-45	5.7	17
811	BRCC3 mutations in myeloid neoplasms. <i>Haematologica</i> , 2015 , 100, 1051-7	6.6	17
810	More is better: combination therapies for myelodysplastic syndromes. <i>Best Practice and Research in Clinical Haematology</i> , 2015 , 28, 22-31	4.2	17
809	Risk for developing myelodysplastic syndromes in prostate cancer patients definitively treated with radiation. <i>Journal of the National Cancer Institute</i> , 2014 , 106, djt462	9.7	17
808	The myelodysplastic syndromes. <i>Expert Opinion on Biological Therapy</i> , 2007 , 7, 369-77	5.4	17
807	Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes. <i>Bone Marrow Transplantation</i> , 2019 , 54, 1281-1286	4.4	17
806	Comprehensive quantitative proteomic profiling of the pharmacodynamic changes induced by MLN4924 in acute myeloid leukemia cells establishes rationale for its combination with azacitidine. <i>Leukemia</i> , 2016 , 30, 1190-4	10.7	16
805	The relationship between eligibility criteria and adverse events in randomized controlled trials of hematologic malignancies. <i>Leukemia</i> , 2017 , 31, 1808-1815	10.7	16
804	ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemia. <i>Blood</i> , 2014 , 123, 3675-7	2.2	16
803	Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide. <i>Journal of Hematology and Oncology</i> , 2012 , 5, 4	22.4	16
802	Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	16

801	Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk Myelodysplastic syndromes with ring sideroblasts. <i>Journal of Hematology and Oncology</i> , 2014 , 7, 89	22.4	16
800	Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with Sweet syndrome that was refractory to 5-azacitidine. <i>Leukemia and Lymphoma</i> , 2014 , 55, 447-9	1.9	16
799	The role of AMG-531 in the treatment of thrombocytopenia in idiopathic thrombocytopenic purpura and myelodysplastic syndromes. <i>Expert Opinion on Biological Therapy</i> , 2008 , 8, 1021-30	5.4	16
798	Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic Models. <i>Blood</i> , 2016 , 128, 216-216	2.2	16
797	Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. <i>Blood Advances</i> , 2019 , 3, 4228-4237	7.8	16
796	Large granular lymphocytic leukemia coexists with myeloid clones and myelodysplastic syndrome. <i>Leukemia</i> , 2020 , 34, 957-962	10.7	16
795	Prediction of CR following a second course of '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course. <i>Leukemia</i> , 2016 , 30, 1779-80	10.7	15
794	Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2014 , 167, 337-45	4.5	15
793	Expression of phosphorylated signal transducer and activator of transcription 5 is associated with an increased risk of death in acute myeloid leukemia. <i>European Journal of Haematology</i> , 2012 , 89, 288-93 ^{3.8}		15
792	Making sense of the myelodysplastic/myeloproliferative neoplasms overlap syndromes. <i>Current Opinion in Hematology</i> , 2014 , 21, 131-40	3.3	15
791	Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide. <i>Leukemia</i> , 2016 , 30, 2405-2409	10.7	14
790	Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC). <i>Leukemia and Lymphoma</i> , 2017 , 58, 1325-1331	1.9	14
789	Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care. <i>Blood Cancer Journal</i> , 2017 , 7, 644	7	14
788	OCT-2 expression and OCT-2/BOB.1 co-expression predict prognosis in patients with newly diagnosed acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2010 , 51, 606-12	1.9	14
787	Impact of weekend admissions on quality of care and outcomes in patients with acute myeloid leukemia. <i>Cancer</i> , 2010 , 116, 3614-20	6.4	14
786	Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin. <i>Clinical Interventions in Aging</i> , 2009 , 4, 197-205	4	14
785	Additional Analyses of a Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117. <i>Blood</i> , 2015 , 126, 908-908	2.2	14
784	Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3328-3339	2.2	14

783	Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3737-3746	2.2	14
782	Molecular features of early onset adult myelodysplastic syndrome. <i>Haematologica</i> , 2017 , 102, 1028-1034	4.6	13
781	Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies. <i>Blood</i> , 2018 , 131, 2782-2788	2.2	13
780	The need for additional genetic markers for myelodysplastic syndrome stratification: what does the future hold for prognostication?. <i>Expert Review of Hematology</i> , 2013 , 6, 59-68	2.8	13
779	Computational drug treatment simulations on projections of dysregulated protein networks derived from the myelodysplastic mutanome match clinical response in patients. <i>Leukemia Research</i> , 2017 , 52, 1-7	2.7	13
778	Epidemiology and risk factors for infections in myelodysplastic syndromes. <i>Transplant Infectious Disease</i> , 2013 , 15, 652-7	2.7	13
777	The avastin story. <i>New England Journal of Medicine</i> , 2011 , 365, 1454-5	59.2	13
776	Phase 3 study of first line pevonedistat (PEV) + azacitidine (AZA) versus single-agent AZA in patients with higher-risk myelodysplastic syndromes (HR MDS), chronic myelomonocytic leukemia (CMML) or low-blast acute myelogenous leukemia (AML).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS7077-TPS7077	2.2	13
775	Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia. <i>Communications Biology</i> , 2020 , 3, 493	6.7	13
774	Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS. <i>Leukemia Research</i> , 2018 , 73, 51-57	2.7	13
773	Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States. <i>Transfusion</i> , 2017 , 57, 289-295	2.9	12
772	Impact of vancomycin-resistant enterococcal bacteremia on outcome during acute myeloid leukemia induction therapy. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2536-42	1.9	12
771	A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia. <i>Leukemia Research</i> , 2010 , 34, 1622-6	2.7	12
770	New data with arsenic trioxide in leukemias and myelodysplastic syndromes. <i>Clinical Lymphoma and Myeloma</i> , 2007 , 8 Suppl 1, S7-S12		12
769	White blood cell count nadir following remission induction chemotherapy is predictive of outcome in older adults with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2007 , 48, 1561-8	1.9	12
768	Treatment with the Thrombopoietin (TPO)-Receptor Agonist Romiplostim in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (Int-1) Risk Myelodysplastic Syndrome (MDS): Results of a Randomized, Double-Blind, Placebo(PBO)-Controlled Study. <i>Blood</i> , 2011 , 118, 117-117	2.2	12
767	Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study. <i>Blood</i> , 2017 , 130, 725-725	2.2	12
766	Myelodysplastic syndromes: recent advancements in risk stratification and unmet therapeutic challenges. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013 ,	7.1	12

765	Fanconi Anemia germline variants as susceptibility factors in aplastic anemia, MDS and AML. <i>Oncotarget</i> , 2018 , 9, 2050-2057	3.3	12
764	Subclonal STAT3 mutations solidify clonal dominance. <i>Blood Advances</i> , 2019 , 3, 917-921	7.8	12
763	Distinct clinical and biological implications of in myeloid neoplasms. <i>Blood Advances</i> , 2019 , 3, 2164-2178	7.8	12
762	Complex landscape of alternative splicing in myeloid neoplasms. <i>Leukemia</i> , 2021 , 35, 1108-1120	10.7	12
761	Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6	11
760	Racial differences in allogeneic hematopoietic cell transplantation outcomes among African Americans and whites. <i>Bone Marrow Transplantation</i> , 2015 , 50, 834-9	4.4	11
759	SF3B1 mutations are infrequently found in non-myelodysplastic bone marrow failure syndromes and mast cell diseases but, if present, are associated with the ring sideroblast phenotype. <i>Haematologica</i> , 2013 , 98, e105-7	6.6	11
758	A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapse. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010 , 10, 473-6	2	11
757	Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy. <i>Oncotarget</i> , 2017 , 8, 81926-81935	3.3	11
756	Impact of allogeneic hematopoietic cell transplant in patients with myeloid neoplasms carrying spliceosomal mutations. <i>American Journal of Hematology</i> , 2016 , 91, 406-9	7.1	11
755	The complexity of interpreting genomic data in patients with acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2016 , 6, e510	7	11
754	Cancer research in the United States: A critical review of current status and proposal for alternative models. <i>Cancer</i> , 2018 , 124, 2881-2889	6.4	10
753	Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine. <i>Leukemia Research</i> , 2017 , 63, 72-77	2.7	10
752	Race and intensity of post-remission therapy in acute myeloid leukemia. <i>Leukemia Research</i> , 2011 , 35, 346-50	2.7	10
751	Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease: implications for clinical trial design and enrollment. <i>Blood</i> , 2009 , 114, 2575-80	2.2	10
750	The role of post-remission chemotherapy for older patients with acute myelogenous leukemia. <i>Leukemia and Lymphoma</i> , 2006 , 47, 689-95	1.9	10
749	Hematologic Improvement-Neutrophil and -Platelet in the MEDALIST Trial: Multilineage Data from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions. <i>Blood</i> , 2019 , 134, 4243-4243	2.2	10
748	A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2019 , 134, 177-177	2.2	10

747	Final Results from a Phase I Combination Study of Lenalidomide and Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2008 , 112, 221-221	2.2	10
746	Overall Survival and Subgroup Analysis from a Randomized Phase III Study of Intravenous Rigosertib Versus Best Supportive Care (BSC) in Patients (pts) with Higher-Risk Myelodysplastic Syndrome (HR-MDS) after Failure of Hypomethylating Agents (HMAs). <i>Blood</i> , 2014 , 124, 163-163	2.2	10
745	Genomics of therapy-related myeloid neoplasms. <i>Haematologica</i> , 2020 , 105, e98-e101	6.6	10
744	Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study. <i>BMC Cancer</i> , 2016 , 16, 652	4.8	10
743	Recent advances in low- and intermediate-1-risk myelodysplastic syndrome: developing a consensus for optimal therapy. <i>Clinical Advances in Hematology and Oncology</i> , 2008 , 6, 1-15	0.6	10
742	Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2723-2726	1.9	9
741	Distinct clinical and biological implications of various DNMT3A mutations in myeloid neoplasms. <i>Leukemia</i> , 2018 , 32, 550-553	10.7	9
740	Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial. <i>Leukemia</i> , 2014 , 28, 2418-21	10.7	9
739	Clinicopathologic and molecular characterization of myeloid neoplasms harboring isochromosome 17(q10). <i>American Journal of Hematology</i> , 2014 , 89, 862	7.1	9
738	Long-Term Outcomes of Hairy Cell Leukemia Treated With Purine Analogs: A Comparison With the General Population. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, 857-862	2	9
737	Allogeneic hematopoietic cell transplantation for myelodysplastic syndromes: lingering uncertainties and emerging possibilities. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 412-20	4.7	9
736	A Randomized, Placebo-Controlled, Phase II Study of Pracinostat in Combination with Azacitidine (AZA) in Patients with Previously Untreated Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2015 , 126, 911-911	2.2	9
735	and mutations in myelodysplastic syndromes (MDS): clonal architecture and impact on outcomes. <i>Leukemia and Lymphoma</i> , 2019 , 60, 1587-1590	1.9	9
734	Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, 528-532	2	9
733	Rethinking clinical trial endpoints in myelodysplastic syndromes. <i>Leukemia</i> , 2019 , 33, 570-575	10.7	8
732	Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy. <i>Leukemia and Lymphoma</i> , 2020 , 61, 1220-1225	1.9	8
731	Are we nearer to curing patients with MDS?. <i>Best Practice and Research in Clinical Haematology</i> , 2010 , 23, 481-7	4.2	8
730	Elevated lactate dehydrogenase is an adverse predictor of outcome in HLA-matched sibling bone marrow transplant for acute myelogenous leukemia. <i>Bone Marrow Transplantation</i> , 2007 , 40, 753-8	4.4	8

729	Older adults with acute myeloid leukemia. <i>Current Oncology Reports</i> , 2002 , 4, 403-9	6.3	8
728	Clinical Benefit of Glasdegib in Combination with Azacitidine or Low-Dose Cytarabine in Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2019 , 134, 3916-3916	2.2	8
727	A Personalized Prediction Model to Risk Stratify Patients with Acute Myeloid Leukemia (AML) Using Artificial Intelligence. <i>Blood</i> , 2019 , 134, 2091-2091	2.2	8
726	Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy. <i>Oncotarget</i> , 2017 , 8, 37866-37874	3.3	8
725	Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial. <i>Annals of Hematology</i> , 2021 , 100, 1181-1194	3	8
724	The euphoria of hypomethylating agents in MDS and AML: is it justified?. <i>Best Practice and Research in Clinical Haematology</i> , 2013 , 26, 275-8	4.2	7
723	Therapy-related myelodysplastic syndromes-specific risk stratification: are we putting the cart before the horse?. <i>Leukemia</i> , 2017 , 31, 2539-2541	10.7	7
722	Histone H4 acetylation by immunohistochemistry and prognosis in relapsed acute lymphocytic leukaemia (ALL). <i>British Journal of Haematology</i> , 2011 , 153, 504-7	4.5	7
721	Timed sequential induction chemotherapy and risk-adapted postremission therapy for acute myelogenous leukemia. <i>American Journal of Hematology</i> , 2008 , 83, 831-4	7.1	7
720	Assessment of Longer-Term Efficacy and Safety in the Phase 3, Randomized, Double-Blind, Placebo-Controlled MEDALIST Trial of Luspatercept to Treat Anemia in Patients (Pts) with Revised International Prognostic Scoring System (IPSS-R) Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC)	2.2	7
719	Phase I Study to Assess the Safety and Tolerability of AZD1152 In Combination with Low Dose Cytosine Arabinoside In Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2010 , 116, 656-656	2.2	7
718	Treatment with the Thrombopoietin (TPO)-Receptor Agonist Romiplostim in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS): Follow-up AML and Survival Results of a Randomized, Double-Blind, Placebo (PBO)-Controlled Study. <i>Blood</i> , 2013 , 122, 121-121	2.2	7
717	Phase 1 Dose-Escalation/Expansion Study Of ARRY-614 In Patients With IPSS Low/Int-1 Risk Myelodysplastic Syndromes. <i>Blood</i> , 2013 , 122, 387-387	2.2	7
716	Panobinostat Plus Azacitidine in Adult Patients with MDS, CMML, or AML: Results of a Phase 2b Study. <i>Blood</i> , 2015 , 126, 2861-2861	2.2	7
715	Validation of International Working Group (IWG) Response Criteria in Higher-Risk Myelodysplastic Syndromes (MDS): A Report on Behalf of the MDS Clinical Research Consortium (MDS CRC). <i>Blood</i> , 2015 , 126, 909-909	2.2	7
714	Low-Dose Hypomethylating Agents (HMAs) Are Effective in Patients (Pts) with Low- or Intermediate-1-Risk Myelodysplastic Syndrome (MDS): A Report on Behalf of the MDS Clinical Research Consortium. <i>Blood</i> , 2015 , 126, 94-94	2.2	7
713	TP53 Mutations and Outcome in Patients with Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2016 , 128, 4336-4336	6.4	7
712	A novel genetic and morphologic phenotype of ARID2-mediated myelodysplasia. <i>Leukemia</i> , 2018 , 32, 839-843	10.7	7

711	Prognostic models in predicting outcomes in myelodysplastic syndromes after hypomethylating agent failure. <i>Leukemia and Lymphoma</i> , 2017 , 58, 2532-2539	1.9	6
710	The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2019 , 60, 3161-3171	1.9	6
709	Therapeutic outcomes using subcutaneous low dose alemtuzumab for acquired bone marrow failure conditions. <i>British Journal of Haematology</i> , 2018 , 183, 133-136	4.5	6
708	Impact of cigarette smoking on survival after myeloablative allogeneic hematopoietic stem cell transplantation and contribution of invasive fungal infection. <i>Bone Marrow Transplantation</i> , 2017 , 52, 1665-1667	4.4	6
707	Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity. <i>Seminars in Hematology</i> , 2017 , 54, 147-153	4.3	6
706	Established and novel agents for myelodysplastic syndromes. <i>Hematology American Society of Hematology Education Program</i> , 2014 , 2014, 82-9	3.1	6
705	A Randomized Controlled Trial of Spiritually-Focused Meditation In Patients Newly Diagnosed with Acute Leukemia.. <i>Blood</i> , 2010 , 116, 1519-1519	2.2	6
704	Impact of Molecular Mutations on Treatment Response to Hypomethylating Agents in MDS. <i>Blood</i> , 2011 , 118, 461-461	2.2	6
703	TP53 Mutation Status Divides MDS Patients with Complex Karyotypes into Distinct Prognostic Risk Groups: Analysis of Combined Datasets from the International Working Group for MDS-Molecular Prognosis Committee. <i>Blood</i> , 2014 , 124, 532-532	2.2	6
702	Mechanisms of Resistance to 5-Azacytidine/Decitabine in MDS-AML and Pre-Clinical In Vivo Proof of Principle of Rational Solutions to Extend Response. <i>Blood</i> , 2015 , 126, 678-678	2.2	6
701	Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML). <i>Blood</i> , 2021 , 138, 246-246	2.2	6
700	Multi-Site 11-Year Experience of Less-Intensive versus Intensive Therapies in Acute Myeloid Leukemia. <i>Blood</i> , 2021 ,	2.2	6
699	Representation of therapy-related myelodysplastic syndrome in clinical trials over the past 20 years. <i>Blood Advances</i> , 2019 , 3, 2738-2747	7.8	6
698	Novel Therapies in Acute Myeloid Leukemia. <i>Seminars in Oncology Nursing</i> , 2019 , 35, 150955	3.7	6
697	Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies. <i>Leukemia</i> , 2019 , 33, 371-378	10.7	6
696	A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy. <i>British Journal of Haematology</i> , 2020 , 188, 404-412	4.5	6
695	Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutions. <i>Cancer</i> , 2018 , 124, 4601-4609	6.4	6
694	Impact of germline CTC1 alterations on telomere length in acquired bone marrow failure. <i>British Journal of Haematology</i> , 2019 , 185, 935-939	4.5	5

693	Genetic and molecular characterization of myelodysplastic syndromes and related myeloid neoplasms. <i>International Journal of Hematology</i> , 2015 , 101, 213-8	2.3	5
692	GvHD-free, relapse-free survival after reduced-intensity allogeneic hematopoietic cell transplantation in older patients with myeloid malignancies. <i>Bone Marrow Transplantation</i> , 2016 , 51, 1642-1643	4.4	5
691	De novo polycythaemia vera arising 5 years following acute myeloid leukemia remission: suggestion of a chemotherapy resistant JAK2 clone. <i>British Journal of Haematology</i> , 2012 , 157, 266-7	4.5	5
690	Differences in genomic patterns and clinical outcomes between African-American and White patients with myelodysplastic syndromes. <i>Blood Cancer Journal</i> , 2017 , 7, e602	7	5
689	Precision Medicine in Myelodysplastic Syndromes and Leukemias: Lessons from Sequential Mutations. <i>Annual Review of Medicine</i> , 2017 , 68, 127-137	17.4	5
688	Ribosomal S6 kinase and AKT phosphorylation as pharmacodynamic biomarkers in patients with myelodysplastic syndrome treated with RAD001. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014 , 14, 172-177.e1	2	5
687	Lenalidomide in MDS: 4th time's a charm. <i>Blood</i> , 2011 , 118, 3757-8	2.2	5
686	How to manage lower-risk myelodysplastic syndromes. <i>Leukemia</i> , 2012 , 26, 390-4	10.7	5
685	A prognostic scoring system for adult patients less than 60 years of age with acute lymphoblastic leukemia in first relapse. <i>Leukemia and Lymphoma</i> , 2009 , 50, 1126-31	1.9	5
684	Time to post-remission therapy is an independent prognostic factor in adults with acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2008 , 49, 1560-6	1.9	5
683	A Study Comparing Dosing Regimens and Efficacy of Subcutaneous to Intravenous Azacitidine (AZA) for the Treatment of Myelodysplastic Syndromes (MDS).. <i>Blood</i> , 2009 , 114, 3797-3797	2.2	5
682	Update of An Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim in Thrombocytopenic Patients with Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2011 , 118, 2772-2772	2.2	5
681	Modified Dose Escalation Of Ruxolitinib: A Feasible Therapeutic Approach In The Management Of Myelofibrosis. <i>Blood</i> , 2013 , 122, 1586-1586	2.2	5
680	Outcome Of Patients (pts) With Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure. <i>Blood</i> , 2013 , 122, 388-388	2.2	5
679	Prediction Of CR On Reinduction In Patients With Newly Diagnosed Acute Myeloid Leukemia Given Intensive Induction Regimens: A Report From SWOG and Cleveland Clinic. <i>Blood</i> , 2013 , 122, 3924-3924	2.2	5
678	Romiplostim in Thrombocytopenic Patients (Pts) with Low-Risk or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) Results in Reduced Bleeding without Impacting Leukemic Progression: Updated Follow-up Results from a Randomized, Double-Blind, Placebo	2.2	5
677	An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2015 , 126, 609-609	2.2	5
676	Incorporation of Molecular Data into the Current Prognostic Models in Treated Patients with Myelodysplastic Syndromes: Which Model Is the Best. <i>Blood</i> , 2016 , 128, 50-50	2.2	5

675	Results of a Phase 3 Study of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles. <i>Blood</i> , 2017 , 130, 891-891	2.2	5
674	Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2900-2904	1.9	5
673	Involving the Public in Rare Cancer Care and Research 2017 , 12-18		4
672	Albumin as a prognostic marker in myelodysplastic syndromes: still relevant after all these years. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2491-2	1.9	4
671	Distinctive and common features of moderate aplastic anaemia. <i>British Journal of Haematology</i> , 2020 , 189, 967-975	4.5	4
670	Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1754-1758	4.7	4
669	Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q). <i>Journal of Hematology and Oncology</i> , 2017 , 10, 131	22.4	4
668	Non-t(6;9) and Non-Inv(3) Balanced Chromosomal Rearrangements Are Associated With Poor Survival Outcomes in Myelodysplastic Syndromes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 489-95	2	4
667	Clinical experiences with ruxolitinib in symptomatic patients with myeloproliferative neoplasm with chronic kidney disease. <i>Leukemia and Lymphoma</i> , 2014 , 55, 213-6	1.9	4
666	Initial transfusion frequency and survival in myelodysplastic syndromes: hopping onto a fast train to nowhere. <i>Leukemia and Lymphoma</i> , 2014 , 55, 2221-2	1.9	4
665	Treatment of MDS: something old, something new, something borrowed. <i>Hematology American Society of Hematology Education Program</i> , 2009 , 656-63	3.1	4
664	Immunomodulation in myelodysplastic syndromes. <i>Best Practice and Research in Clinical Haematology</i> , 2006 , 19, 757-67	4.2	4
663	Glasdegib in Addition to Intensive or Non-Intensive Chemotherapy in Patients with Acute Myeloid Leukemia: Safety Analysis of Glasdegib 'On Target' Adverse Events. <i>Blood</i> , 2018 , 132, 2732-2732	2.2	4
662	Time from Diagnosis to Treatment Initiation Predicts Survival in Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2007 , 110, 598-598	2.2	4
661	Preliminary Results of a Phase 1/2, Multi-Center, Open-Label Study (CLL- 001) Investigating a Stepwise Dose-Escalation Schedule of Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2008 , 112, 2104-2104	2.2	4
660	Survival, Prognostic Factors, and Rates of Leukemic Transformation in a Multicenter Study of 303 Untreated Patients with MDS and Del(5q).. <i>Blood</i> , 2009 , 114, 945-945	2.2	4
659	Mutational Spectrum In Chronic Myelomonocytic Leukemia Includes Genes Associated with Epigenetic Regulation Such as UTX and EZH2. <i>Blood</i> , 2010 , 116, 611-611	2.2	4
658	Lintuzumab and Low-Dose Cytarabine Compared to Placebo and Low-Dose Cytarabine in Patients with Untreated Acute Myeloid Leukemia (AML) 60 Years and Older: Results of a Randomized, Double-Blinded Phase 2b Study,. <i>Blood</i> , 2011 , 118, 3613-3613	2.2	4

657	Impact Of Cytogenetics and Cytogenetic Response On Outcome In Myelodysplastic Syndromes (MDS) treated With Azacitidine (AZA). A Collaborative Study In 878 Patients. <i>Blood</i> , 2013 , 122, 389-389	2.2	4
656	In Analogy to AML, MDS Can be Sub-Classified By Ancestral Mutations. <i>Blood</i> , 2014 , 124, 823-823	2.2	4
655	Impact of Comorbidities at Diagnosis of Acute Myeloid Leukemia on One-Year Mortality. <i>Blood</i> , 2015 , 126, 532-532	2.2	4
654	The Use of Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML): Clinical Outcomes and Their Predictors in a Large International Patient Cohort. <i>Blood</i> , 2016 , 128, 1063-1063	2.2	4
653	Feasibility of Allogeneic Hematopoietic Cell Transplantation Among High-Risk AML Patients in First Complete Remission: Results of the Transplant Objective from the SWOG (S1203) Randomized Phase III Study of Induction Therapy Using Standard 7+3 Therapy or Idarubicin with High-Dose Cytarabine (IA) Versus IA Plus Vorinostat. <i>Blood</i> , 2016 , 128, 1166-1166	2.2	4
652	On the Edge of Life, I: Assessment of, Reaction to, and Management of the Terminally Ill Recorded in an Intensive Care Unit Journal. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2002 , 4, 178-183		4
651	Novel invariant features of Good syndrome. <i>Leukemia</i> , 2021 , 35, 1792-1796	10.7	4
650	Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia. <i>Clinical Cancer Research</i> , 2021 , 27, 6095-6105	12.9	4
649	Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: is it any good?. <i>Psychophysiology</i> , 2005 , 4, 182-5		4
648	A drug's life: the pathway to drug approval. <i>Clinical Advances in Hematology and Oncology</i> , 2013 , 11, 646-655		4
647	Low-Dose Cytarabine With or Without Glasdegib in Newly Diagnosed Patients with Acute Myeloid Leukemia: Long-Term Analysis of a Phase 2 Randomized Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, S228-S229	2	3
646	Mitigating Fear and Loathing in Managing Acute Myeloid Leukemia. <i>Seminars in Hematology</i> , 2015 , 52, 249-55	4	3
645	Managing patients with higher-risk myelodysplastic syndrome with stable disease on hypomethylating agents. <i>Leukemia and Lymphoma</i> , 2015 , 56, 3267-9	1.9	3
644	Large granular lymphocytic leukaemia after solid organ and haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2020 , 189, 318-322	4.5	3
643	Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response. <i>Leukemia and Lymphoma</i> , 2018 , 59, 363-371	1.9	3
642	Improving the diagnosis and treatment of patients with myelodysplastic syndromes through a performance improvement initiative. <i>Leukemia Research</i> , 2013 , 37, 422-6	2.7	3
641	Blood consult: treating del(5q) myelodysplastic syndromes. <i>Blood</i> , 2012 , 119, 342-4	2.2	3
640	What's all the fuss about? facts and figures about bone marrow failure and conditions. <i>Current Hematologic Malignancy Reports</i> , 2012 , 7, 300-9	4.4	3

639	Baseline characteristics and predictors of outcome in patients with myelodysplastic syndromes living in Western Pennsylvania. <i>Leukemia and Lymphoma</i> , 2011 , 52, 265-72	1.9	3
638	Active Treatment Strategies Improving Outcomes in Patients with Myelodysplastic Syndromes with the Deletion 5q Abnormality. <i>Clinical Leukemia</i> , 2008 , 2, 28-33		3
637	Arsenic trioxide as a treatment for myelodysplastic syndrome. <i>Current Hematologic Malignancy Reports</i> , 2006 , 1, 34-8	4.4	3
636	Alternative treatments for myelodysplastic syndromes. <i>Seminars in Hematology</i> , 2005 , 42, S32-7	4	3
635	Non-transplant therapy for older adults with acute myeloid leukemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2006 , 4, 51-6	7.3	3
634	Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Combination with Azacitidine or Daratumumab in Non-APL Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2018 , 132, 2735-2735	2.2	3
633	What Is the Optimal Time to Initiate Hypomethylating Agents (HMA) in Higher Risk Myelodysplastic Syndromes (MDS)?. <i>Blood</i> , 2018 , 132, 3098-3098	2.2	3
632	Luspatercept Significantly Reduces Red Blood Cell (RBC) Transfusion Burden, Regardless of Gene Mutation Frequency, Spectrum, and Prognostic Significance, Among Patients (Pts) with LR-MDS Enrolled in the MEDALIST Trial. <i>Blood</i> , 2019 , 134, 2999-2999	2.2	3
631	Effects of the Therapeutic Armamentarium on Survival and Time to Next Treatment in CMML Subtypes: An International Analysis of 950 Cases Coordinated By the AGMT Study Group. <i>Blood</i> , 2019 , 134, 844-844	2.2	3
630	Efficacy and Safety of Luspatercept Treatment in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T): A Retrospective Analysis from the Medalist Study. <i>Blood</i> , 2020 , 136, 13-15	2.2	3
629	Preliminary Results from a Phase I Study of Revlimid [®] (Lenalidomide) in Combination with Vidaza [®] (Azacitidine) in Patients with Advanced Myelodysplastic Syndromes (MDS).. <i>Blood</i> , 2007 , 110, 1458-1458 ^{2,2}		3
628	Lenalidomide-Induced Cytopenias: Relationship to Hematologic Improvement in Patients with Myelodysplastic Syndromes (MDS).. <i>Blood</i> , 2007 , 110, 821-821	2.2	3
627	Establishment of Myelodysplastic Syndrome-Specific Methylome: Implications for the Pathogenesis of Clonal Evolution and Association with Survival. <i>Blood</i> , 2008 , 112, 850-850	2.2	3
626	Perceptions of Disease State, Treatment Expectations, and Prognosis Among Patients with Myelodysplastic Syndromes.. <i>Blood</i> , 2009 , 114, 1771-1771	2.2	3
625	Secondary Resistance to Lenalidomide in Del(5q) MDS Is Associated with CDC25C & PP2A Overexpression.. <i>Blood</i> , 2009 , 114, 292-292	2.2	3
624	Validating the Lower-Risk MD Anderson Prognostic Scoring System (LR-PSS) and the Revised International Prognostic Scoring System (IPSS-R) for Patients with Myelodysplastic Syndromes. <i>Blood</i> , 2011 , 118, 1720-1720	2.2	3
623	A Phase 1 Study of Sequential Idarubicin + Cytarabine, Followed by Lenalidomide, in Patients with Previously Untreated Acute Myeloid Leukemia (AML). <i>Blood</i> , 2011 , 118, 2600-2600	2.2	3
622	Determination of a Phase II Dose of Panobinostat in Combination with 5-Azacitidine in Patients with Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia. <i>Blood</i> , 2011 , 118, 459-459	2.2	3

621	Non-Cytotoxic Differentiation Therapy Based On Mechanism of Disease Produces Complete Remission in Myelodysplastic Syndromes (MDS) with High Risk Cytogenetics. <i>Blood</i> , 2012 , 120, 1696-1696 ^{2,2}	3
620	Treatment With Romiplostim, a Thrombopoietin-Receptor Agonist, In Thrombocytopenic Patients With Low Or Intermediate-1 Risk Myelodysplastic Syndrome: Updated Follow-Up Results For Acute Myeloid Leukemia and Survival From a Randomized, Double-Blind, Placebo-Controlled Study. <i>Blood</i> , 2015 , 122, 1553-1553	2.2 3
619	Outcomes of Patients with Myelodysplastic Syndromes (MDS) Who Achieve Stable Disease after Treatment with Hypomethylating Agents (HMA). <i>Blood</i> , 2014 , 124, 3273-3273	2.2 3
618	Treatment with Romiplostim, a Thrombopoietin-Receptor Agonist, in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (Int-1) Risk Myelodysplastic Syndrome (MDS): Updated Follow-up Results for Acute Myeloid Leukemia (AML) and Survival from a Randomized, Double-Blind, Placebo (PBO)-Controlled Study. <i>Blood</i> , 2014 , 124, 3273-3273	2.2 3
617	p53 Mutant Independently Impacts Risk: Analysis of Deletion 5q, Lower-Risk Myelodysplastic Syndromes (MDS) Patients Treated with Lenalidomide (LEN) in the MDS-004 Study. <i>Blood</i> , 2014 , 124, 414-414	2.2 3
616	Bortezomib + MEC (Mitoxantrone, Etoposide, Cytarabine) for Relapsed/ Refractory Acute Myeloid Leukemia: Final Results of an Expanded Phase 1 Trial. <i>Blood</i> , 2014 , 124, 978-978	2.2 3
615	Long-Term Outcome of Myelodysplastic Syndromes (MDS) Patients Treated with Erythropoiesis Stimulating Agents (ESAs). <i>Blood</i> , 2015 , 126, 1696-1696	2.2 3
614	Effect of Lenalidomide (LEN) Exposure on AML-Free Survival and Overall Survival in LEN-Treated Patients (Pts) with IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS) with Del(5q). <i>Blood</i> , 2015 , 126, 2870-2870	2.2 3
613	The Revised International Prognostic Scoring System "Molecular" (IPSS-Rm), a Validated and Dynamic Model in Treated Patients with Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2015 , 126, 607-607	2.2 3
612	Prognostic Impact of Molecular Mutations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) on Allogeneic Hematopoietic Cell Transplant (HCT) Outcomes: Adverse Impact of TET2 Mutations. <i>Blood</i> , 2015 , 126, 740-740	2.2 3
611	A Randomized Phase II Study of Low-Dose Decitabine Versus Azacitidine in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium. <i>Blood</i> , 2016 , 128, 226-226	2.2 3
610	PHF6 Somatic Mutations and Their Functional Role in the Pathophysiology of Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016 , 128, 2736-2736	2.2 3
609	Current Diagnosis Patterns for Acute Myeloid Leukemia (AML) in Clinical Practice Compared with World Health Organization (WHO) 2008 Recommendations: Outcomes from the CONNECT ² Myelodysplastic Syndromes (MDS) and AML Disease Registry. <i>Blood</i> , 2016 , 128, 3548-3548	2.2 3
608	Optimal Treatment Order of Lenalidomide and Hypomethylating Agents for Lower-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium. <i>Blood</i> , 2016 , 128, 4322-4322	2.2 3
607	Pevedistat (PEV) + Azacitidine (AZA) Versus AZA Alone As First-Line Treatment for Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) with 20-30% Marrow Blasts: The Randomized Phase 3 PANTHER Trial (NCT03268954). <i>Blood</i> , 2021 , 138, 242-242	2.2 3
606	Failure to detect mutations U2AF1 due to changes in the GRCh38 reference sequence	3
605	Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia. <i>Blood</i> , 2021 , 138, 1885-1895	2.2 3
604	Improving Prognostic Modeling in Myelodysplastic Syndromes. <i>Current Hematologic Malignancy Reports</i> , 2016 , 11, 395-401	4.4 3

603	Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria. <i>Blood Cells, Molecules, and Diseases</i> , 2021 , 87, 102528	2.1	3
602	Arsenic trioxide as a treatment for myelodysplastic syndrome. <i>Psychophysiology</i> , 2005 , 4, 59-63		3
601	Primary Melanoma of the Lung 2017 , 285-292		2
600	Uncommon Hepatobiliary Tumors 2017 , 444-457		2
599	Borderline Tumors of the Ovary 2017 , 572-581		2
598	Uncommon Presentations of Plasma Cell Dyscrasias 2017 , 776-792		2
597	Comprehensive Management of Chordoma 2017 , 847-855		2
596	Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents. <i>Leukemia Research</i> , 2020 , 99, 106472	2.7	2
595	Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey. <i>Leukemia and Lymphoma</i> , 2020 , 61, 1455-1464	1.9	2
594	Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, e597-e605	2	2
593	Myelodysplastic syndromes spatial clusters in disease etiology and outcome. <i>Leukemia and Lymphoma</i> , 2016 , 57, 392-399	1.9	2
592	My AML cytogenetics classification scheme is better than yours. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 160-1	4.7	2
591	Uncommon Cancers of the Bladder 2012 , 23-33		2
590	Germ Cell Tumors of the Ovary 2012 , 519-530		2
589	Phyllodes Tumor of the Breast 2012 , 243-256		2
588	Uncommon Tumors of the Kidney 2012 , 1-22		2
587	The race for survival in myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2013 , 54, 219-20	1.9	2
586	A case of mistaken identity: When lupus masquerades as primary myelofibrosis. <i>SAGE Open Medical Case Reports</i> , 2013 , 1, 2050313X13498709	0.7	2

585	Rare Tumors of the Testis and Paratesticular Tissues 2012 , 77-96		2
584	Uncommon Cancers of the Prostate 2012 , 47-75		2
583	Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: Is it any good?. <i>Current Hematologic Malignancy Reports</i> , 2006 , 1, 16-9	4.4	2
582	Outcomes of Patients with Hematologic Malignancies and COVID-19 Infection: A Report from the ASH Research Collaborative Data Hub. <i>Blood</i> , 2020 , 136, 7-8	2.2	2
581	Failure to detect mutations in U2AF1 due to changes in the GRCh38 reference sequence.. <i>Journal of Molecular Diagnostics</i> , 2022 ,	5.1	2
580	Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients with Myelodysplastic Syndromes (MDS): Results of a Large Web-Based Survey. <i>Blood</i> , 2018 , 132, 1825-1825	2.2	2
579	Genomic Biomarkers Predict Response/Resistance to Lenalidomide in Non-Del(5q) Myelodysplastic Syndromes. <i>Blood</i> , 2018 , 132, 1797-1797	2.2	2
578	Diagnosis of Myelodysplastic Syndromes and Related Conditions: Rates of Discordance between Local and Central Review in the NHLBI MDS Natural History Study. <i>Blood</i> , 2018 , 132, 4370-4370	2.2	2
577	Geno-Clinical Model for the Diagnosis of Bone Marrow Myeloid Neoplasms. <i>Blood</i> , 2019 , 134, 4238-4238	2.2	2
576	FA Gene Carrier Status Predisposes to Myeloid Neoplasms and Bone Marrow Failure in Adults. <i>Blood</i> , 2019 , 134, 452-452	2.2	2
575	The Impact of Comorbidities and Organ Dysfunction Commonly Used for Clinical Trial Eligibility Criteria on Outcome in Acute Myeloid Leukemia (AML) Patients Receiving Induction Chemotherapy. <i>Blood</i> , 2019 , 134, 16-16	2.2	2
574	Pattern of Somatic Mutation Changes from Diagnosis to Relapse Following Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2019 , 134, 2716-2716	2.2	2
573	Impact and Outcomes of RAS gene Mutations in Core Binding Factor Acute Myeloid Leukemia. <i>Blood</i> , 2019 , 134, 2720-2720	2.2	2
572	TET Dioxygenase Inhibition As a Therapeutic Strategy in TET2 Mutant Myeloid Neoplasia. <i>Blood</i> , 2019 , 134, 880-880	2.2	2
571	A Personalized Clinical-Decision Tool to Improve the Diagnostic Accuracy of Myelodysplastic Syndromes. <i>Blood</i> , 2020 , 136, 33-35	2.2	2
570	A Decision Analysis To Determine the Appropriate Treatment for Low-Risk Myelodysplastic Syndromes.. <i>Blood</i> , 2005 , 106, 2533-2533	2.2	2
569	Phase I/II, Randomized, MultiCenter, Dose-Ascension Study of the p38MAPK Inhibitor Scio-469 in Patients with Myelodysplastic Syndrome (MDS).. <i>Blood</i> , 2006 , 108, 2657-2657	2.2	2
568	Chemotherapy-Related Amenorrhea (CRA) among Premenopausal Patients Treated for Acute Leukemia.. <i>Blood</i> , 2006 , 108, 3315-3315	2.2	2

567	Update from an Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim In Thrombocytopenic Patients (Pts) with Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2010 , 116, 1885-1885	2.2	2
566	A Phase II Study of Lenalidomide for Previously Untreated Deletion (del) 5q Acute Myeloid Leukemia (AML) Patients Age 60 or Older Who Are Not Candidates for Remission Induction Chemotherapy (Southwest Oncology Group Study S0605). <i>Blood</i> , 2010 , 116, 332-332	2.2	2
565	Phase 2 Multicenter Trial of Rabbit Anti-Thymocyte Serotherapy In Myelodysplastic Syndrome: Rate of Hematological Improvement Associated with Pre-Treatment Disease Duration. <i>Blood</i> , 2010 , 116, 602-602	2.2	2
564	Association of SF3B1 with Ring Sideroblasts in patients, In Vivo, and In Vitro models of Spliceosomal Dysfunction. <i>Blood</i> , 2011 , 118, 457-457	2.2	2
563	Somatic Mutations in Schinzel-Giedion Syndrome Gene SETBP1 Determine Progression in Myeloid Malignancies. <i>Blood</i> , 2012 , 120, 2-2	2.2	2
562	Development and Validation of a Model to Predict Response to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndromes (MDS).. <i>Blood</i> , 2012 , 120, 2801-2801	2.2	2
561	Defining Central Line-Associated Blood Stream Infections Following Hematopoietic Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome.. <i>Blood</i> , 2012 , 120, 3042-3042	2.2	2
560	Association Of Large Granular Lymphocytic Leukemia (LGL) With B-Cell Lymphoproliferative Disorders. <i>Blood</i> , 2013 , 122, 1387-1387	2.2	2
559	Comparing The Prognostic Value Of Risk Stratifying Models For Patients With Lower-Risk Myelodysplastic Syndromes (MDS): Is One Model Better? A Report on The Behalf of The MDS Clinical Research Consortium. <i>Blood</i> , 2013 , 122, 1505-1505	2.2	2
558	Time Changes In Predictive Power Of MDS Prognostic Scores ¶Effects On Revised Scores Such As The IPSS-R, Impact Of Age. <i>Blood</i> , 2013 , 122, 1544-1544	2.2	2
557	Splicing Factor 3b Subunit 1 (SF3B1) Heterozygous Mice Manifest a Hematologic Phenotype Similar To Low Risk Myelodysplastic Syndromes With Ring Sideroblasts. <i>Blood</i> , 2013 , 122, 259-259	2.2	2
556	Association Of Cytogenetic Response (CyR) With RBC Transfusion-Independence (RBC-TI) and AML-Free Survival In Lenalidomide (LEN)-Treated Patients (Pts) With IPSS Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) With Del(5q). <i>Blood</i> , 2013 , 122, 390-390	2.2	2
555	Rates of Infection in Myelofibrosis Patients Treated with Ruxolitinib. <i>Blood</i> , 2014 , 124, 1835-1835	2.2	2
554	Outcome of Newly Diagnosed Acute Myeloid Leukemia (AML) Refractory to 1 or 2 Cycles of Induction Chemotherapy. <i>Blood</i> , 2015 , 126, 1319-1319	2.2	2
553	Response to Treatment Among SF3B1 Mutated Myelodysplastic Syndromes (MDS): A Case-Control Study from the MDS Clinical Research Consortium (MDS CRC). <i>Blood</i> , 2015 , 126, 1697-1697	2.2	2
552	Survival Outcomes of Leukemias and Myelodysplastic Syndromes Occurring As Second Cancers in the United States: A SEER Registry-Based Population Analysis. <i>Blood</i> , 2015 , 126, 2507-2507	2.2	2
551	Phase 1 Study of AMG 900, an Orally Administered Pan-Aurora Kinase Inhibitor, in Adult Patients (Pts) with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015 , 126, 4929-4929	2.2	2
550	Serial Sequencing in Myelodysplastic Syndromes Reveals Dynamic Changes in Clonal Architecture and Allows for a New Prognostic Assessment of Mutations Detected in Cross-Sectional Testing. <i>Blood</i> , 2015 , 126, 709-709	2.2	2

549	Frequency and Prognostic Significance of Cytogenetic Abnormalities in 1269 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2016 , 128, 112-112	2.2	2
548	Complete Remissions (CRs) with Azacitidine Regimens Compared to Crs with 7+3 Induction Chemotherapy and the Effect on Overall Survival. <i>Blood</i> , 2016 , 128, 1613-1613	2.2	2
547	Forty-Year Analysis of Randomized Clinical Trials in Patients with Acute Myeloid Leukemia Treated with Remission Induction Chemotherapy. <i>Blood</i> , 2016 , 128, 2786-2786	2.2	2
546	Clonal Dynamics of Refractory Aplastic Anemia in Patients Treated with Eltrombopag. <i>Blood</i> , 2016 , 128, 3892-3892	2.2	2
545	Genetic and Epigenetic Defects in the Autophagy Machinery in Myelodysplastic Syndromes. <i>Blood</i> , 2016 , 128, 4301-4301	2.2	2
544	A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia Undergoing Remission Induction Therapy. <i>Blood</i> , 2016 , 128, 447-447	2.2	2
543	NGS-Based Copy Number Analysis in 1,185 Patients with Myeloid Neoplasms. <i>Blood</i> , 2016 , 128, 955-955	2.2	2
542	Impact of allogeneic hematopoietic stem cell transplant (HSCT) on patients harboring the spliceosome mutation SRSF2.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 7008-7008	2.2	2
541	Transplant Referral Patterns for Patients (Pts) with Newly Diagnosed (ND) Higher-Risk (HR) Myelodysplastic Syndromes (MDS), and European Leukemianet (ELN) 2010 Intermediate-Risk (IR) or Adverse-Risk (AR) Acute Myeloid Leukemia (AML) in the Connect MDS/AML Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, S98-S99	4.7	2
540	Low participation rates and disparities in participation in interventional clinical trials for myelodysplastic syndromes. <i>Cancer</i> , 2020 , 126, 4735-4743	6.4	2
539	Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes. <i>International Journal of Laboratory Hematology</i> , 2021 , 43, 426-432	2.5	2
538	Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium. <i>Cancer Medicine</i> , 2021 , 10, 447-453	4.8	2
537	Analysis of distinct hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasia. <i>Leukemia and Lymphoma</i> , 2021 , 62, 735-738	1.9	2
536	A Phase II Trial of Imatinib Mesylate as Maintenance Therapy for Patients With Newly Diagnosed C-kit-positive Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, 113-118	2	2
535	Reply to A. Piccardo et al, E. Hindi et al, M.C. Kreissl et al, M. Doss, J. Buscombe, R. Fisher, M. Sollini et al, M. Lichtenstein, and M. Tulchinsky et al. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1889-1892	2.2	2
534	Denial's Many Faces. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1374-1375	2.2	2
533	The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q). <i>Blood Cancer Journal</i> , 2018 , 8, 90	7	2
532	Strategies for success in creating an effective multihospital health-system pharmacy and therapeutics committee. <i>American Journal of Health-System Pharmacy</i> , 2018 , 75, 451-455	2.2	2

531	A geno-clinical decision model for the diagnosis of myelodysplastic syndromes. <i>Blood Advances</i> , 2021 , 5, 4361-4369	7.8	2
530	Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better? 2015 , 90, 1036		2
529	Large Cell Neuroendocrine Carcinoma 2017 , 293-304		1
528	Rare Tumors of the Larynx 2017 , 152-164		1
527	Nasopharyngeal Carcinoma in Nonendemic Populations 2017 , 165-195		1
526	What Patients Need to Know 2017 , 6-11		1
525	Metaplastic Breast Cancer 2017 , 327-337		1
524	Breast Cancer in Men 2017 , 364-376		1
523	Uncommon Adrenal Tumors in Children and Adolescents 2017 , 1126-1137		1
522	Is the cure the poison? The evolving story of therapy-related myeloid malignancies. <i>Leukemia and Lymphoma</i> , 2015 , 56, 839-40	1.9	1
521	Results of a Phase 1/2a dose-escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2020 , 61, 1943-1953	1.9	1
520	Screening for SF3B1 mutations is a useful tool to differentiate between acquired clonal and non-clonal sideroblastic anemia. <i>Leukemia and Lymphoma</i> , 2015 , 56, 1888-90	1.9	1
519	Treating myelodysplastic syndromes: is more better?. <i>Lancet Haematology, the</i> , 2015 , 2, e2-3	14.6	1
518	Myeloproliferative Neoplasms: Chronic Myelogenous Leukemia, Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis 2012 , 647-658		1
517	Parathyroid Carcinoma 2012 , 201-209		1
516	Uncommon Tumors of the Esophagus 2012 , 373-388		1
515	Cancers of the Small Bowel 2012 , 441-451		1
514	Flying without a net in MDS. <i>Blood</i> , 2013 , 122, 2925-6	2.2	1

513	The baby whisperer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4584-5	2.2	1
512	The revolution of myelodysplastic syndromes. <i>Therapeutic Advances in Hematology</i> , 2011 , 2, 33-43	5.7	1
511	Very superstitious. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3026-7	2.2	1
510	Uncommon Adrenal Tumors in Children and Adolescents 2012 , 903-914		1
509	Stromal Tumors of the Ovary 2012 , 507-518		1
508	Chordomas 2012 , 721-732		1
507	A Phase I/II Trial of CPX-351 + Palbociclib in Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2020 , 136, 13-14	2.2	1
506	Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia.. <i>Journal of Clinical Investigation</i> , 2022 ,	15.9	1
505	Factors Associated with Early Therapy Initiation in Patients (pts) with Myelodysplastic Syndromes (MDS) in the Connect MDS/AML Disease Registry. <i>Blood</i> , 2018 , 132, 4731-4731	2.2	1
504	LUC7L2 Is a Novel RNA-Splicing Regulatory Factor Mutated in Myelodysplastic Syndromes. <i>Blood</i> , 2018 , 132, 3073-3073	2.2	1
503	Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: A Large Real-Time Multi-Center Prospective Longitudinal Observational Study. <i>Blood</i> , 2018 , 132, 207-207	2.2	1
502	Impact of Venous Thromboembolism during High Intensity Chemotherapy for Acute Leukemia Patients on Duration of Hospital Stay. <i>Blood</i> , 2018 , 132, 4806-4806	2.2	1
501	Clinical Outcomes for Patients with Myeloid Malignancies Harboring IDH1/2 mutations after Intensive Chemotherapy. <i>Blood</i> , 2018 , 132, 1389-1389	2.2	1
500	Somatic Mutations in Therapy-Related Myeloid Neoplasms Are Influenced By Therapeutic Modality and Clonal Hematopoiesis of Indeterminate Potential. <i>Blood</i> , 2018 , 132, 3084-3084	2.2	1
499	RORA Is a Potential Prognostic Biomarker and Therapeutic Target for Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2019 , 134, 2696-2696	2.2	1
498	How Morphologic Features Are Shaped By Underlying Somatic Genotype in MDS. <i>Blood</i> , 2019 , 134, 1716-1716	2.2	1
497	Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes. <i>Blood</i> , 2019 , 134, 1715-1715	2.2	1
496	Mutational Patterns and Clonal Architecture of Therapy-Related Acute Myeloid Leukemia. <i>Blood</i> , 2019 , 134, 1405-1405	2.2	1

495	The Clonal Trajectories of SF3B1 Mutations in Myeloid Neoplasia. <i>Blood</i> , 2020 , 136, 8-8	2.2	1
494	Genotype-Phenotype Correlations in Patients with Myeloid Malignancies Using Explainable Artificial Intelligence. <i>Blood</i> , 2020 , 136, 31-32	2.2	1
493	Targeted Sequencing of 7 Genes Can Help Reduce Pathologic Misclassification of MDS. <i>Blood</i> , 2020 , 136, 32-33	2.2	1
492	Time to Post-Remission Therapy (PRT) Is an Independent Prognostic Factor for Relapse and Overall Survival in Adults with Acute Lymphocytic Leukemia (ALL).. <i>Blood</i> , 2006 , 108, 1883-1883	2.2	1
491	SNP Karyotyping in Myelodysplastic Syndromes (MDS) Reveals the Presence of Cryptic Karyotypic Abnormalities, Including Uniparental Disomy, and Has Important Prognostic Implications.. <i>Blood</i> , 2006 , 108, 853-853	2.2	1
490	Phase I Study of Clofarabine with Standard-Dose Infusional Cytarabine (Ara-C) as Intensive Induction Therapy for Newly-Diagnosed De Novo Acute Myeloid Leukemia in Older Adults Age ≥ 60 Years.. <i>Blood</i> , 2007 , 110, 1831-1831	2.2	1
489	Characteristics of Patients with Myelodysplastic Syndromes (MDS) in the United States from 4528 Physician Surveys.. <i>Blood</i> , 2007 , 110, 2462-2462	2.2	1
488	Comparison of Prognostic Factors and Outcomes of Patients with Secondary Acute Myeloid Leukemia (AML) Following Myelodysplastic Syndromes (MDS), Myeloproliferative Disorders (MPD), or Therapy-Related AML (t-AML).. <i>Blood</i> , 2007 , 110, 4292-4292	2.2	1
487	Effectiveness of Peripheral Blood (PB) Molecular Monitoring by Quantitative RT-PCR (Q-PCR) in Phase II Acute Promyelocytic Leukemia (APL) Trial J0422.. <i>Blood</i> , 2008 , 112, 1502-1502	2.2	1
486	Chromosomal defects Detected by SNP-Array-Based Karyotyping Are Independent Predictors of Survival in Acute Myeloid Leukemia (AML). <i>Blood</i> , 2008 , 112, 431-431	2.2	1
485	Development of a Prognostic Scoring System for Secondary Acute Myeloid Leukemia (sAML) Arising from Myelodysplastic Syndromes (MDS), Myeloproliferative Disorders (MPD), or Therapy-Related AML (t-AML).. <i>Blood</i> , 2008 , 112, 921-921	2.2	1
484	Race and Intensity of Post-Remission Therapy in Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2009 , 114, 1012-1012	2.2	1
483	A Phase II Multicentre Study with Elacytarabine as Second Salvage Therapy in Patients with AML.. <i>Blood</i> , 2009 , 114, 1042-1042	2.2	1
482	Non-p53 Dependent, Leukemia Initiating-Cell Selective, Therapy.. <i>Blood</i> , 2009 , 114, 2077-2077	2.2	1
481	An Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim in Thrombocytopenic Patients (Pts) with Myelodysplastic Syndromes (MDS).. <i>Blood</i> , 2009 , 114, 2765-2765	2.2	1
480	Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study). <i>Blood</i> , 2010 , 116, 1376-1376	2.2	1
479	Preliminary Results of Fixed-Dose Oral Clofarabine (CLO) In Patients Who Have Failed Hypomethylating Agents for the Treatment of Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2010 , 116, 1869-1869 ¹	2.2	1
478	Outcomes In Acute Myeloid Leukemia (AML) Patients Diagnosed with Myeloid Sarcoma with and without Bone Marrow Involvement. <i>Blood</i> , 2010 , 116, 2165-2165	2.2	1

477	Phase 2 Randomized Multicenter Study of Extended Dosing Schedules of Oral Ezatiostat HCl (Telintra), a Glutathione Analog Prodrug GSTP1-1 Inhibitor, In Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2010 , 116, 2910-2910	2.2	1
476	Therapeutic Response to Azacitidine (AZA) In Patients with Secondary Myelodysplastic Syndromes (sMDS) Enrolled In the AVIDA Registry. <i>Blood</i> , 2010 , 116, 2931-2931	2.2	1
475	Cytogenetic Predictors of Response to Lenalidomide In Myeloid Malignancies without Del(5q). <i>Blood</i> , 2010 , 116, 4016-4016	2.2	1
474	Prior Therapy with DNA Methyltransferase Inhibitors (DNMTI) Predicts for Lower Remission Rates and Worse Survival In Secondary Acute Myeloid Leukemia Patients (sAML) Receiving Remission Induction Therapy. <i>Blood</i> , 2010 , 116, 4033-4033	2.2	1
473	Phase Ib Study of Oral Panobinostat In Combination with 5-Azacitidine (5-aza) In Patients with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). <i>Blood</i> , 2010 , 116, 4957-4957	2.2	1
472	Fluoroquinolone Prophylaxis in Acute Myeloid Leukemia (AML) Patients Undergoing Post-Remission Chemotherapy Reduces Hospital Admission Rates. <i>Blood</i> , 2011 , 118, 2570-2570	2.2	1
471	Association of Changes in Transfusion Status with Changes in Health-Related Quality of Life of Real-World Patients with MDS Across Six Months of Treatment with Azacitidine. <i>Blood</i> , 2011 , 118, 2796-2796	2.2	1
470	Cigarette Smoking Significantly Increases the Risk of Invasive Fungal Disease (IFD) in Acute Myeloid Leukemia (AML) Patients Undergoing Induction Chemotherapy. <i>Blood</i> , 2011 , 118, 3595-3595	2.2	1
469	Final Results From the Phase 2 Continuation Study of the Lenalidomide and Azacitidine Combination in Patients with Higher-Risk Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2011 , 118, 607-607	2.2	1
468	Impact of Day 28 Absolute Lymphocyte Count On Outcome of Hematopoietic Cell Transplant (HCT) in CR1 for Adult Patients with Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012 , 120, 1472-1472	2.2	1
467	Vancomycin-Resistant Enterococcus (VRE) Bacteremia During Acute Myeloid Leukemia (AML) Induction Therapy Is an Independent Predictor of Poor Outcome. <i>Blood</i> , 2012 , 120, 1487-1487	2.2	1
466	Whole Exome Sequencing to Predict Response to Hypomethylating Agents in MDS. <i>Blood</i> , 2012 , 120, 1698-1698	2.2	1
465	Mutation Screening Associated with Chromosome 7 Abnormalities Using Next Generation Whole Exome Sequencing. <i>Blood</i> , 2012 , 120, 173-173	2.2	1
464	Impact of Mutations in the Spliceosome Machinery and Ring Sideroblasts in Patients with Myeloid Malignancies Who Received Conventional Chemotherapy or Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2012 , 120, 1973-1973	2.2	1
463	The Molecular and Cytokine Profile of Triple-Negative (JAK2 V617F, JAK2 exon 12, MPL negative) Myelofibrosis, a Myeloproliferative Neoplasm with Distinct Clinico-Pathologic Characteristics. <i>Blood</i> , 2012 , 120, 3805-3805	2.2	1
462	A Specific Mechanism By Which NPM1 mutations Impede Myeloid Differentiation Also Explains The Link With DNMT3A Mutation. <i>Blood</i> , 2013 , 122, 1254-1254	2.2	1
461	Splicing Factor 3b Subunit 1 (SF3B1) mediates Mitochondrial Iron Overload In Myelodysplastic Syndromes With Ring Sideroblasts By Alternative Splicing Of Mitoferrin-1 (SLC25A37). <i>Blood</i> , 2013 , 122, 1555-1555	2.2	1
460	Inhibition Of JAK-STAT Pathway As a Therapeutic Option For Myelofibrosis Associated Pulmonary Hypertension. <i>Blood</i> , 2013 , 122, 1585-1585	2.2	1

459	Molecular Characterization Of Myeloid Neoplasms Harboring Isochromosome 17q Abnormality. <i>Blood</i> , 2013 , 122, 2596-2596	2.2	1
458	BCL-2 Family Of Genes Is a Key Regulator In The Pathogenesis Of SF3B1 Mutant and Wild Type MDS With Ring Sideroblasts and Represents a Novel Drug Target In This Disease. <i>Blood</i> , 2013 , 122, 263-263	2.2	1
457	Molecular Defects In BRCC3 Complex, a Novel Pathogenic Pathway In MDS. <i>Blood</i> , 2013 , 122, 264-264	2.2	1
456	LFA-3/CD2 Pathway, Potential Target For Immunosuppressive Therapy In Aplastic Anemia: A Phase I/II Trial Of Alefacept In Patients With Relapsed/Refractory Aplastic Anemia. <i>Blood</i> , 2013 , 122, 3711-3711 ^{2.2}	2.2	1
455	Spliceosomal Gene LUC7L2 Mutation Causes Missplicing and Alteration Of Gene Expression In Myeloid Neoplasms. <i>Blood</i> , 2013 , 122, 470-470	2.2	1
454	Clinical MUTATOMEIDf Myelodysplastic Syndrome; Comparison To Primary Acute Myelogenous Leukemia. <i>Blood</i> , 2013 , 122, 518-518	2.2	1
453	Somatic Mutational Screen For Improved Prediction Of The Outcomes Of Epigenetic Therapy In MDS. <i>Blood</i> , 2013 , 122, 659-659	2.2	1
452	Distinct Pattern Of Genomic Changes Associated With Smoking In Patients With Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2013 , 122, 660-660	2.2	1
451	The Impact of Clonal Architecture of IDH1 and IDH2 Mutant Cases on the Biology of Myeloid Malignancies. <i>Blood</i> , 2014 , 124, 1897-1897	2.2	1
450	Doctor-Patient Communication and Perception of Treatment Discontinuation in Myelodysplastic Syndromes (MDS) Diverge at the Time of Disease Progression. <i>Blood</i> , 2014 , 124, 2642-2642	2.2	1
449	Molecular Predictors of Response in Patients with Myeloid Neoplasms Treated with Lenalidomide. <i>Blood</i> , 2014 , 124, 4665-4665	2.2	1
448	An International Data Set for the Study of Chronic Myelomonocytic Leukemia (CMML) Validates Modern Prognostic Scoring Systems and Demonstrates a Critical Need for Novel Prognostication Strategies. <i>Blood</i> , 2014 , 124, 530-530	2.2	1
447	Somatic Mutations in Splicing Factor 3b, Subunit 1 (SF3B1) Are a Useful Biomarker to Differentiate Between Clonal and Non-Clonal Causes of Sideroblastic Anemia. <i>Blood</i> , 2014 , 124, 5597-5597	2.2	1
446	PHF6 - Somatic Mutations and Their Role in Pathophysiology of MDS and AML. <i>Blood</i> , 2015 , 126, 1259-1259	2.2	1
445	TET 2 Alterations in Myeloid Malignancies, Impact on Clinical Characteristics, Outcome, and Disease Predisposition. <i>Blood</i> , 2015 , 126, 1645-1645	2.2	1
444	Elevated Basal Autophagy in SF3B1 Mutated Myelodysplastic Syndromes: Relationship with Survival Outcomes and Therapeutic Implications. <i>Blood</i> , 2015 , 126, 1647-1647	2.2	1
443	Molecular Predictors of Response in Patients with Myeloid Neoplasms Treated with Lenalidomide. <i>Blood</i> , 2015 , 126, 2853-2853	2.2	1
442	Impact of Cytogenetic Abnormalities and Cytogenetic Response to Hypomethylating Agents (HMAs) in Patients (pts) with Lower Risk Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2015 , 126, 2877-2877 ^{2.2}	2.2	1

441	Prognostic Impact of Rare Single Abnormalities in Myelodysplastic Syndromes. <i>Blood</i> , 2015 , 126, 2879-2879		1
440	Impact of Eltrombopag on Expansion of Clones with Somatic Mutations in Refractory Aplastic Anemia. <i>Blood</i> , 2015 , 126, 300-300	2.2	1
439	Molecular and Immunophenotypic Characteristics of Adult Acute Leukemias of Ambiguous Lineage. <i>Blood</i> , 2016 , 128, 1659-1659	2.2	1
438	Is Serial Monitoring of Myeloid Mutations Clinically Relevant in Myelodysplastic Syndromes (MDS): A Report on Behalf of the MDS Clinical Research Consortium (CRC). <i>Blood</i> , 2016 , 128, 297-297	2.2	1
437	U2AF1 Mutations in S34 and Q157 Create Distinct Molecular and Clinical Contexts. <i>Blood</i> , 2016 , 128, 3155-3155	2.2	1
436	Pathogenic Relevance of Germ Line TET2 Alterations. <i>Blood</i> , 2016 , 128, 3160-3160	2.2	1
435	Analysis of Outcomes of Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated in Randomized Clinical Trials. <i>Blood</i> , 2016 , 128, 4000-4000	2.2	1
434	Clonal Events of Aplastic Anemia Related to the Evolution to Myelodysplastic Syndrome. <i>Blood</i> , 2016 , 128, 4290-4290	2.2	1
433	Lowering the boom on lower-risk myelodysplastic syndromes. <i>Hematology American Society of Hematology Education Program</i> , 2019 , 2019, 367-372	3.1	1
432	Prognostic and predictive value of IPSS-R in assessing overall survival (OS) in a phase III study of rigosertib in second-line higher-risk (HR) MDS patients.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 7092-7092	2.2	1
431	Overall survival (OS) and baseline disease characteristics in MDS patients with primary HMA failure in a randomized, controlled, phase III study of rigosertib.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e18079-e18079	2.2	1
430	Glasdegib in combination with azacitidine (AZA) in patients (pts) with untreated higher-risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML): Effects on marrow recovery and transfusion independence.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 7501-7501	2.2	1
429	Myelodysplastic Syndromes: Recent Advancements in Risk Stratification and Unmet Therapeutic Challenges. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013 , e256-e270	7.1	1
428	Chemotherapy-Related Mutational Signatures Reveal the Origins of Therapy-Related Myeloid Neoplasms. <i>Blood</i> , 2021 , 138, 3271-3271	2.2	1
427	Presence of JAK2 Mutations in MDS/MPD-u WHO Classified Patients and Not Other Forms of MDS Suggests Their Derivation from Classical Myeloproliferative Syndrome.. <i>Blood</i> , 2005 , 106, 369-369	2.2	1
426	A Phase II Trial of Combination Therapy with Arsenic Trioxide (ATO) and Gemtuzumab Ozogamicin (GO) in Patients with High-Risk Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) Arising from MDS.. <i>Blood</i> , 2006 , 108, 2669-2669	2.2	1
425	Lactate Dehydrogenase (LDH) Level Predicts the Outcome of Patients with Acute Myelogenous Leukemia (AML) Following HLA-Matched Sibling Bone Marrow Transplant (BMT).. <i>Blood</i> , 2006 , 108, 3013-3013	2.2	1
424	Characteristics, Treatment Patterns and Outcomes Among Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Who Present with Hyperleukocytosis: Findings from a Large International Patient Cohort. <i>Blood</i> , 2018 , 132, 4040-4040	2.2	1

423	Genetics of Monosomy 7 and Del(7q) in MDS Informs Potential Therapeutic Targets. <i>Blood</i> , 2019 , 134, 1703-1703	2.2	1
422	Differences in Genomic Patterns and Clinical Outcomes Between African-American and White Patients with Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2014 , 124, 3274-3274	2.2	1
421	APC mutations in myeloid malignancies: Incidence and impact on leukemogenesis.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 11047-11047	2.2	1
420	The Complete Mutatome and Clonal Architecture of Del(5q). <i>Blood</i> , 2015 , 126, 608-608	2.2	1
419	Prognostic Impact of Molecular Mutations in AML at First Relapse. <i>Blood</i> , 2015 , 126, 3825-3825	2.2	1
418	Impact of Red Blood Cell and Platelet Transfusions in Acute Myeloid Leukemia (AML) Patients Undergoing Remission Induction Chemotherapy. <i>Blood</i> , 2015 , 126, 2127-2127	2.2	1
417	Targeting Autophagy in Myelodysplastic Syndromes. <i>Blood</i> , 2016 , 128, 4295-4295	2.2	1
416	Importance of Complete Remission on Predicting Overall Survival in Patients with Lower-Risk Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2016 , 128, 4332-4332	2.2	1
415	A Prognostic Scoring System for Patients \geq 60 Years of Age with Acute Lymphocytic Leukemia in First Relapse.. <i>Blood</i> , 2008 , 112, 901-901	2.2	1
414	Impact of TET2 mutations On Responsiveness to Demethylating Agents in MDS.. <i>Blood</i> , 2009 , 114, 1606-1606	2.2	1
413	Higher Rates of AML Transformation and Poor Risk Cytogenetics in Patients with Low Average Albumin Levels Confers Poor Prognosis in Myelodysplastic Syndromes,. <i>Blood</i> , 2011 , 118, 3832-3832	2.2	1
412	A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Bortezomib for Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2012 , 120, 3595-3595	2.2	1
411	Novel Pathogenic Defects Of Dead/H-Box Helicases In Myeloid Neoplasms. <i>Blood</i> , 2013 , 122, 655-655	2.2	1
410	Clonal dynamics of aplastic anemia/paroxysmal nocturnal hemoglobinuria. <i>Leukemia and Lymphoma</i> , 2020 , 61, 1242-1245	1.9	1
409	Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect MDS/AML Disease Registry. <i>EJHaem</i> , 2020 , 1, 58-68	0.9	1
408	Under COVID of the night. <i>Blood</i> , 2020 , 136, 2844-2845	2.2	1
407	Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic review. <i>PLoS ONE</i> , 2021 , 16, e0249087	3.7	1
406	IMerge: A phase 3 study to evaluate imetelstat in transfusion-dependent subjects with IPSS low or intermediate-1 risk myelodysplastic syndromes that are relapsed/refractory to erythropoiesis-stimulating agent treatment.. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS7056-TPS7056	2.2	1

405	What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)?. <i>Leukemia and Lymphoma</i> , 2021 , 62, 2762-2767	1.9	1
404	Leukemia evolving from paroxysmal nocturnal hemoglobinuria. <i>Leukemia</i> , 2020 , 34, 327-330	10.7	1
403	Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS). <i>Cancer</i> , 2021 , 127, 4421-4431	6.4	1
402	A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes.. <i>Annals of Hematology</i> , 2022 , 1	3	1
401	Uncommon Tumors of the Kidney 2017 , 19-40		0
400	Uncommon Cancers of the Bladder 2017 , 41-53		0
399	Metaplastic Breast Carcinoma 2012 , 211-216		0
398	Tumors of the Vulva and Vagina 2012 , 587-599		0
397	REVELation (del: 5q). <i>Blood</i> , 2009 , 113, 3888-9	2.2	0
396	Less intensive antileukemic therapies (monotherapy and/or combination) for older adults with acute myeloid leukemia who are not candidates for intensive antileukemic therapy: A systematic review and meta-analysis.. <i>PLoS ONE</i> , 2022 , 17, e0263240	3.7	0
395	Can Monosomy 7 be Targeted By Next Generation Cereblon-Modulating Agents?. <i>Blood</i> , 2019 , 134, 1270-1270	2.2	0
394	DDX41 Is a Tumor Suppressor Gene Associated with Inherited and Acquired Mutations. <i>Blood</i> , 2014 , 124, 125-125	2.2	0
393	Subcutaneous Low Dose Alemtuzumab: Role As a Salvage Therapy in Immune -Mediated Marrow Failure Conditions. <i>Blood</i> , 2016 , 128, 1505-1505	2.2	0
392	Treatment Patterns and Outcomes of Patients with Lower-Risk Myelodysplastic Syndromes in the Connect ☐ Myeloid Disease Registry. <i>Blood</i> , 2021 , 138, 3686-3686	2.2	0
391	Treatment Patterns and Survival Outcomes of Patients with Acute Myeloid Leukemia Who Achieved Remission in the Connect ☐ Myeloid Disease Registry. <i>Blood</i> , 2021 , 138, 279-279	2.2	0
390	Sabatolimab (MBG453) Combination Treatment Regimens for Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS): The MDS Studies in the Stimulus Immuno-Myeloid Clinical Trial Program. <i>Blood</i> , 2021 , 138, 4669-4669	2.2	0
389	c-Kit (CD117) Expression Is a Poor Prognostic Factor for Relapse and Overall Survival in Patients with Newly Diagnosed AML.. <i>Blood</i> , 2006 , 108, 4510-4510	2.2	0
388	Analysis of Immunogenetic Factors in Myelodysplastic Syndromes (MDS) Reveals Potential Pathogenic Role Cytokine Genotypes Such as TGF-☐ <i>Blood</i> , 2007 , 110, 2446-2446	2.2	0

387	Patient Derived Xenografts (PDX) Recapitulate Ruxolitinib Clinical Trial Responses and Identify a Novel Combination Therapy for Chronic Myelomonocytic Leukemia (CMML). <i>Blood</i> , 2019 , 134, 2984-2984	2.2	○
386	Are Racial Disparities in Acute Myeloid Leukemia (AML) Clinical Trial Enrollment Associated with Comorbidities and/or Organ Dysfunction?. <i>Blood</i> , 2019 , 134, 381-381	2.2	○
385	Hotspot U2AF1 Mutations Determine Missplicing Selectivity: Novel Mechanisms Altering Splicing Factors. <i>Blood</i> , 2019 , 134, 2985-2985	2.2	○
384	Impact of Day 28 Absolute Lymphocyte Count on Outcome of Adult Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2014 , 124, 5256-5256	2.2	○
383	Activation of the Unfolded Protein Response with the First-in-Class P97 Inhibitor CB-5083 Induces Stable Disease Regression and Overcomes Ara-C Resistance in AML. <i>Blood</i> , 2015 , 126, 1350-1350	2.2	○
382	Differential Response to Hypomethylating Agents Based on Sex: A Report on Behalf of the MDS Clinical Research Consortium (MDS CRC). <i>Blood</i> , 2015 , 126, 2889-2889	2.2	○
381	Germline Events In GFI1 In Myelodysplastic Syndrome. <i>Blood</i> , 2013 , 122, 1231-1231	2.2	○
380	Targeting health-related quality of life in patients with myelodysplastic syndromes - Current knowledge and lessons to be learned. <i>Blood Reviews</i> , 2021 , 50, 100851	11.1	○
379	Clonal trajectories and cellular dynamics of myeloid neoplasms with SF3B1 mutations. <i>Leukemia</i> , 2021 , 35, 3324-3328	10.7	○
378	Influence of Killer Immunoglobulin-Like Receptors and Somatic Mutations on Transplant Outcomes in Acute Myeloid Leukemia. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 917.e1-917.e9		○
377	Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis. <i>Leukemia and Lymphoma</i> , 2021 , 1-6	1.9	○
376	Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q. <i>EBioMedicine</i> , 2022 , 80, 104059	8.8	○
375	Time, timing, and the treatment of diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016 , 57, 247-248	1.9	
374	Lung Adenocarcinoma 2017 , 305-314		
373	Adrenal Neoplasms 2017 , 681-712		
372	A Structured Approach to Uncommon Cancers 2017 , 1-5		
371	Uncommon Tumors of the Oral Cavity and Adjacent Structures 2017 , 134-151		
370	Esthesioneuroblastoma 2017 , 196-213		

- 369 Thymoma and Thymic Carcinoma **2017**, 214-247
- 368 Primary Sarcomas of the Lung **2017**, 248-265
- 367 Mesothelioma **2017**, 266-284
- 366 Primary Adenoid Cystic Carcinoma of the Lung **2017**, 315-326
- 365 Tubular Carcinoma of the Breast **2017**, 338-344
- 364 Breast Sarcoma **2017**, 345-356
- 363 Adenoid Cystic Carcinoma of the Breast **2017**, 357-363
- 362 Uncommon Tumors of the Esophagus **2017**, 377-394
- 361 Uncommon Cancers of the Stomach **2017**, 395-415
- 360 Uncommon Cancers of the Small Bowel **2017**, 416-428
- 359 Uncommon Cancers of the Pancreas **2017**, 429-443
- 358 Unusual Tumors of the Colon, Rectum, and Anus **2017**, 458-469
- 357 Gastrointestinal Stromal Tumors **2017**, 470-492
- 356 Surgery for Uncommon Gynecological Cancers **2017**, 493-507
- 355 Histologies That Cross Organ Types **2017**, 508-517
- 354 Germ Cell Tumors of the Ovary **2017**, 518-532
- 353 Sex Cord-Stromal Tumors of the Ovary **2017**, 533-549
- 352 Clear Cell Carcinoma of the Ovary **2017**, 550-556

351 Mucinous Carcinoma of the Ovary **2017**, 557-563

350 Low-Grade Serous Carcinoma of the Ovary **2017**, 564-571

349 Fallopian Tube and Peritoneal Cancers **2017**, 582-590

348 Nonendometrioid Endometrial Carcinomas and Uterine Sarcomas **2017**, 591-617

347 Tumors of the Cervix **2017**, 618-642

346 Tumors of the Vulva and Vagina **2017**, 643-652

345 Targeted Therapy in Gynecological Malignancy **2017**, 663-680

344 Uncommon Cancers of the Thyroid **2017**, 713-729

343 Parathyroid Carcinoma **2017**, 730-739

342 Rare Acute Leukemias **2017**, 740-751

341 Unusual Myelodysplastic and Myelodysplastic/Myeloproliferative Neoplasms **2017**, 752-759

340 Rare B Cell Lymphoproliferative Disorders **2017**, 760-775

339 Rare Bone Marrow Failure Conditions **2017**, 793-815

338 Myeloproliferative Neoplasms **2017**, 816-829

337 Rare T Cell Lymphomas **2017**, 830-839

336 Primary Melanotic Tumors of the Central Nervous System **2017**, 840-846

335 Atypical and Malignant Meningiomas **2017**, 856-870

334 Urethral Cancer **2017**, 54-67

- 333 Primary Central Nervous System Lymphoma **2017**, 871-882
- 332 Choroid Plexus Tumors **2017**, 883-887
- 331 Diffuse Low-Grade Gliomas **2017**, 888-898
- 330 High-Grade Gliomas **2017**, 899-906
- 329 Ependymomas **2017**, 907-916
- 328 Medulloblastoma in Adults **2017**, 917-938
- 327 Pineal Parenchymal Tumors **2017**, 939-948
- 326 Craniopharyngiomas **2017**, 949-963
- 325 Ophthalmic Cancers **2017**, 964-975
- 324 Unusual Cutaneous Malignancies **2017**, 976-993
- 323 Uncommon Cancers of the Prostate **2017**, 68-96
- 322 Unusual Melanomas **2017**, 1002-1021
- 321 Uncommon Tumors of Soft Tissue **2017**, 1022-1068
- 320 Introduction to Rare Pediatric Malignancies **2017**, 1069-1071
- 319 Uncommon Tumors of the Gastrointestinal Tract in Children **2017**, 1072-1087
- 318 Rare Pediatric Malignancies of the Head and Neck **2017**, 1088-1096
- 317 Uncommon Pediatric Tumors of the Thorax **2017**, 1097-1125
- 316 Uncommon Pediatric Genitourinary Tumors **2017**, 1138-1151

315 Uncommon Pediatric Brain Tumors **2017**, 1152-1171

314 Rare Tumors of the Testis and Paratesticular Tissues **2017**, 97-121

313 Malignant Tumors of the Skin and Subcutaneous Tissue in Children **2017**, 1172-1189

312 Rare Hematological Malignancies in Children **2017**, 1190-1201

311 Penile Carcinoma **2017**, 122-133

310 Wilms tumor 1 expression: addressing the 'elephant' in MDS. *Leukemia and Lymphoma*, **2019**, 60, 566-567.9

309 Combination therapies for MDS and AML: Does one plus one equal one?. *Leukemia and Lymphoma*, **2016**, 57, 505-6 1.9

308 Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. *Leukemia and Lymphoma*, **2019**, 60, 246-249 1.9

307 The puzzle of cancer recovery. *Journal of Clinical Oncology*, **2014**, 32, 3075-6 2.2

306 Thymoma and Thymic Carcinoma **2012**, 279-301

305 Male Breast Cancer **2012**, 233-241

304 Glioma and Other Neuroepithelial Neoplasms **2012**, 767-794

303 Langerhans Cell Histiocytosis of the Central Nervous System **2012**, 715-720

302 Extraovarian Primary Peritoneal Carcinomas **2012**, 485-495

301 Fallopian Tube Cancer **2012**, 531-539

300 Gastrointestinal Stromal Tumors **2012**, 465-483

299 Borderline Tumors and Other Rare Epithelial Tumors of the Ovary **2012**, 497-506

298 Nasopharyngeal Carcinoma in Nonendemic Populations **2012**, 131-150

- 297 Adenoid Cystic Carcinoma of the Breast **2012**, 217-224
- 296 Large Cell Neuroendocrine Carcinoma **2012**, 343-353
- 295 Hematological Malignancies Uncommon Presentations of Plasma Cell Dyscrasias **2012**, 627-635
- 294 Atypical and Malignant Meningiomas **2012**, 733-745
- 293 Uncommon Cancers of the Stomach **2012**, 389-408
- 292 Reply to H. Kantarjian et al. *Journal of Clinical Oncology*, **2013**, 31, 1796 2.2
- 291 If Nostradamus were treated for MDS. *Blood*, **2011**, 117, 374-5 2.2
- 290 How flipping burgers can cure leukemia. *Journal of Clinical Oncology*, **2010**, 28, 3096-7 2.2
- 289 A hallmark moment. *Journal of Clinical Oncology*, **2010**, 28, 5348-9 2.2
- 288 Clofarabine for myelodysplastic syndromes. *Expert Opinion on Investigational Drugs*, **2011**, 20, 1005-14 5.9
- 287 What my patients taught me about love. *Journal of Clinical Oncology*, **2009**, 27, 4817-8 2.2
- 286 A piece of my mind. The road warriors. *JAMA - Journal of the American Medical Association*, **2011**, 306, 805-6 27.4
- 285 Uncommon Pediatric Brain Tumors **2012**, 927-942
- 284 Pineal Parenchymal Tumors **2012**, 813-821
- 283 Uncommon Pediatric Tumors of the Thorax **2012**, 877-901
- 282 Adrenal Neoplasms **2012**, 163-187
- 281 Uncommon Cancers of the Thyroid **2012**, 189-200
- 280 Non-Hodgkin Lymphoma of the Breast **2012**, 225-232

279 Carcinosarcoma of the Breast **2012**, 257-269

278 Tubular Carcinoma **2012**, 271-277

277 Primary Sarcomas of the Lung **2012**, 303-317

276 Mesotheliomas **2012**, 319-334

275 Primary Melanoma of the Lung **2012**, 335-341

274 Bronchioloalveolar Carcinoma of the Lung **2012**, 355-363

273 Primary Adenoid Cystic Carcinoma of the Lung **2012**, 365-372

272 Unusual Cancers of the Pancreas **2012**, 409-421

271 Urethral Cancer **2012**, 35-46

270 Uncommon Hepatobiliary Tumors **2012**, 423-440

269 Unusual Tumors of the Colon, Rectum, And Anus **2012**, 453-463

268 Nonendometrioid Endometrial Carcinomas and Uterine Sarcomas **2012**, 541-565

267 Tumors of the Cervix **2012**, 567-585

266 Rare Acute Leukemias **2012**, 601-609

265 Unusual Myelodysplastic Syndromes and Myeloproliferative Neoplasms **2012**, 613-616

264 Rare B Cell Lymphoproliferative Disorders **2012**, 617-626

263 Rare Bone Marrow Failure Conditions **2012**, 637-646

262 Uncommon Tumors of the Oral Cavity and Adjacent Structures **2012**, 97-117

261 Esthesioneuroblastoma **2012**, 151-162

260 Rare T Cell Lymphomas **2012**, 659-666

259 Unusual Cutaneous Malignancies **2012**, 667-683

258 Unusual Melanomas **2012**, 691-708

257 Primary Melanotic Tumors of the Central Nervous System **2012**, 709-714

256 Primary Central Nervous System Lymphoma **2012**, 747-757

255 Choroid Plexus Papilloma and Carcinoma **2012**, 759-766

254 Medulloblastoma in Adults **2012**, 795-811

253 Craniopharyngiomas **2012**, 823-834

252 Ophthalmic Cancers **2012**, 835-846

251 Introduction to Rare Cancers of Childhood **2012**, 847-849

250 Uncommon Tumors of the Gastrointestinal Tract in Children **2012**, 851-865

249 Rare Pediatric Malignancies of the Head And Neck **2012**, 867-875

248 Uncommon Pediatric Genitourinary Tumors **2012**, 915-926

247 Malignant Tumors of the Skin and Subcutaneous Tissue in Children **2012**, 943-957

246 Rare Tumors of the Larynx **2012**, 119-130

245 Enrollment Criteria for Clinical Trials in Acute Myeloid Leukemia. *Clinical Leukemia*, **2009**, 3, 14-19

244 Azacitidine in Myelodysplastic Syndromes. *Drugs*, **2005**, 65, 1790-1791

12.1

243	Type of TP53 Mutations Affects Subclonal Configuration and Selection Pressure for Acquisition of Additional Hits in Contralateral Alleles. <i>Blood</i> , 2020 , 136, 25-25	2.2
242	Multicenter Validation of a Personalized Model to Predict Hypomethylating Agent Response in Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2020 , 136, 54-55	2.2
241	The Genomic Landscape of Wilms' Tumor 1 (WT1) Mutant Acute Myeloid Leukemia. <i>Blood</i> , 2020 , 136, 28-28	2.2
240	Molecular and Expression Characterization of Monosomy 7 and Del(7q). <i>Blood</i> , 2020 , 136, 33-33	2.2
239	Increased Productivity and Efficiency Among Cancer Center Clinical Trials Workforce during the COVID-19 Pandemic. <i>Blood</i> , 2020 , 136, 41-42	2.2
238	Double Genetic Hits and Subclonal Mosaicism in the Ras Signaling Pathway in Myeloid Neoplasia. <i>Blood</i> , 2020 , 136, 34-35	2.2
237	TET2 Inhibitory Effects of Eltrombopag Contribute Its Hematopoietic Activity. <i>Blood</i> , 2020 , 136, 2-3	2.2
236	Outcomes for Hispanic Patients with Acute Leukemia Treated at Academic Centers. <i>Blood</i> , 2021 , 138, 2282-2282	2.2
235	COVID-19 Outcomes Among Participants in the NHLBI Myelodysplastic Syndromes (MDS) Natural History Study. <i>Blood</i> , 2021 , 138, 2611-2611	2.2
234	Octogenarians with AML Can Have Durable Remissions with Venetoclax and Hypomethylating Agent Therapy Despite Significant Dose Reductions. <i>Blood</i> , 2021 , 138, 1259-1259	2.2
233	Use of High Dose Cytarabine (HiDAC) for Post-Remission or Re-Induction Therapy Is Safe and Effective in Select Older AML Patients. <i>Blood</i> , 2021 , 138, 4422-4422	2.2
232	Risks for Hospitalization and Death Among Patients with Blood Disorders from the ASH RC COVID-19 Registry for Hematology. <i>Blood</i> , 2021 , 138, 3040-3040	2.2
231	Clinical Predictors of Outcome in Adult Patients with Acute Leukemias and Myelodysplastic Syndrome and COVID-19 Infection: Report from the American Society of Hematology Research Collaborative (ASH RC) Data Hub. <i>Blood</i> , 2021 , 138, 280-280	2.2
230	On the Edge of Life, II: House Officer Struggles Recorded in an Intensive Care Unit Journal. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2002 , 4, 184-190	
229	A Psychosocial Assessment of Patients before and after Autologous Stem Cell Transplantation.. <i>Blood</i> , 2004 , 104, 3152-3152	2.2
228	Epsilon Aminocaproic Acid (EACA) Reduces Transfusion Requirements in Patients with Thrombocytopenic Hemorrhage.. <i>Blood</i> , 2004 , 104, 3938-3938	2.2
227	Psychosocial Factors in Decision-Making of Patient Eligibility for Allogeneic Bone Marrow Transplantation.. <i>Blood</i> , 2004 , 104, 3324-3324	2.2
226	Time to Nadir Peripheral White Blood Cell Count (WBC) and Absolute WBC Nadir Value Following Induction Chemotherapy in Older Adults with Acute Myeloid Leukemia (AML) Predicts Survival.. <i>Blood</i> , 2004 , 104, 1074-1074	2.2

- 225 The Relationship between Weekend Admissions and Outcome in Older Adults with Acute Myelogenous Leukemia (AML).. *Blood*, **2004**, 104, 3140-3140 2.2
- 224 High-Resolution Genomic Scan for Cryptic Chromosomal Lesions in MDS and AML.. *Blood*, **2004**, 104, 3427-3427 2.2
- 223 Survival and Predictors of Outcome in Acute Leukemia Patients Admitted to the Intensive Care Unit.. *Blood*, **2005**, 106, 2778-2778 2.2
- 222 Phase I/II Study of Clofarabine Combined with Standard Dose Cytarabine as Remission Induction Therapy of De Novo AML in Elderly Patients \geq 60 Years.. *Blood*, **2005**, 106, 4635-4635 2.2
- 221 A Pilot Application of SELDI-TOF Mass Spectrometry in Bone Marrow Failure Syndromes.. *Blood*, **2005**, 106, 3421-3421 2.2
- 220 A Phase 2, Single-Arm, Open-Label Trial To Evaluate the Effectiveness of Darbepoetin alfa for the Treatment of Anemia in Patients with Low-Risk Myelodysplastic Syndrome.. *Blood*, **2005**, 106, 2541-2541^{2,2}
- 219 Increased Frequency of Polymorphisms in XRCC3 and OGG1 Genes in Patients with MDS.. *Blood*, **2005**, 106, 3445-3445 2.2
- 218 Cytogenetic Classification Systems and Overall Survival Following Bone Marrow Transplant (BMT) for Acute Myelogenous Leukemia (AML).. *Blood*, **2005**, 106, 4500-4500 2.2
- 217 CD117 Expression Is a Poor Prognostic Factor (PF) for Progression Free Survival (PFS) and Freedom from Progression (FFP) in Patients with Newly Diagnosed Acute Myelogenous Leukemia (AML).. *Blood*, **2005**, 106, 3292-3292 2.2
- 216 A Quality of Life Assessment of Ablative Allogeneic Bone Marrow Transplant (BMT) Recipients One and Twelve Months after Transplant.. *Blood*, **2005**, 106, 1322-1322 2.2
- 215 High-Resolution Genomic Arrays Facilitate Detection of Novel Cryptic Chromosomal Lesions in MDS.. *Blood*, **2005**, 106, 370-370 2.2
- 214 Prognostic Factors and Outcomes of Patients with Acute Myeloid Leukemia (AML) Receiving Non Intensive Chemotherapy (NIC) or Best Supportive Care (BSC).. *Blood*, **2006**, 108, 4492-4492 2.2
- 213 High-Density SNP Arrays Reveals the Possible Presence of Multi-Loci Genetic Predisposition for Myelodysplastic Syndromes (MDS).. *Blood*, **2006**, 108, 2643-2643 2.2
- 212 Defects of Base Excision Repair Involving OGG1 Can Be Detected in a Subset of Patients with MDS and May Convey Propensity to Chromosomal Breaks.. *Blood*, **2006**, 108, 2631-2631 2.2
- 211 SNP Array Analysis in Refractory Anemia with Ringed Sideroblast Allows for Detection of a High Frequency of Previously Cryptic Chromosomal Defects with Possible Clinical Significance.. *Blood*, **2006**, 108, 2352-2352 2.2
- 210 The Efficacy and Safety of Darbepoetin Alfa for Treating Anemia in Low-Risk Myelodysplastic Syndrome Patients: Results after 53/55 Weeks.. *Blood*, **2006**, 108, 2671-2671 2.2
- 209 Hemochromatosis-Associated Gene Mutations in Patients with Myelodysplastic Syndromes with Refractory Anemia and Ringed Sideroblasts.. *Blood*, **2006**, 108, 1541-1541 2.2
- 208 Whole Genome 250K SNP Array Allows for Detection of Previously Unidentified Lesions in Chromosome 5 in Patients with MDS.. *Blood*, **2006**, 108, 2350-2350 2.2

207	Impact of Socioeconomic Status and Distance from Treatment Center on Survival in Patients Receiving Remission Induction Therapy for Newly Diagnosed Acute Myelogenous Leukemia (AML).. <i>Blood</i> , 2006 , 108, 1920-1920	2.2
206	Blasts Express Phospho-Akt in the Majority of Adult Patients with Acute Lymphocytic Leukemia (ALL).. <i>Blood</i> , 2006 , 108, 1846-1846	2.2
205	Prior Therapy with Rituximab (R) in Patients with Follicular Lymphoma (FL) Does Not Affect Relapse-Free (RFS) or Overall Survival (OS) after High Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT).. <i>Blood</i> , 2006 , 108, 3069-3069	2.2
204	A Phase II Trial of Combination Therapy with Thalidomide, Arsenic Trioxide, Dexamethasone, and Ascorbic Acid (TADA) in Patients with Chronic Idiopathic Myelofibrosis (CIMF) or Overlap Myelodysplastic/Myeloproliferative Diseases (MDS/MPD).. <i>Blood</i> , 2006 , 108, 4886-4886	2.2
203	Overexpression of MPG Is Associated with Distinct Defects in Base Excision Repair in a Subgroup of Patients with MDS.. <i>Blood</i> , 2006 , 108, 2646-2646	2.2
202	Impact of Genetic Polymorphisms on Immune Response and Clinical Features in MDS.. <i>Blood</i> , 2006 , 108, 2670-2670	2.2
201	A Phase II Trial of Combination Therapy with Thalidomide, Arsenic Trioxide, Dexamethasone, and Ascorbic Acid (TADA) in Patients with Overlap Myelodysplastic/Myeloproliferative Diseases (MDS/MPD) or Chronic Idiopathic Myelofibrosis (CIMF).. <i>Blood</i> , 2007 , 110, 1457-1457	2.2
200	Detection of Recurrent Uniparental Disomy and Cryptic Chromosomal Abnormalities in MDS/MPD-U and MDS/MPD-Derived Secondary AML. <i>Blood</i> , 2007 , 110, 1542-1542	2.2
199	Immunogenetic Analysis Reveals the Association of INF- γ (+874 A/T) Hypersecretor Genotype in AA and a Low Frequency of KIR-2DL3/C1 Mismatch in Responders to Immunosuppression.. <i>Blood</i> , 2007 , 110, 1700-1700	2.2
198	Histone H4 Acetylation Is Associated with Improved Relapse-Free Survival in Newly Diagnosed Patients with Acute Lymphoblastic Leukemia (ALL) Less Than 60 Years of Age without Poor Risk Cytogenetics.. <i>Blood</i> , 2007 , 110, 2798-2798	2.2
197	SNP-Array-Based Karyotyping Has Impact on Cytogenetic Diagnosis and Prognosis of Non-Core Binding Factor Primary and Secondary AML.. <i>Blood</i> , 2007 , 110, 597-597	2.2
196	High Throughput Methylation Arrays Allow for Identification of Complex Methylation Patterns in MDS.. <i>Blood</i> , 2007 , 110, 2437-2437	2.2
195	A Phase 1 Trial of Imatinib Mesylate in Combination with Daunorubicin and Cytarabine for Patients for C-kit Positive Relapsed Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2007 , 110, 906-906	2.2
194	SNP Array Karyotyping Improves Detection Rate of Clonal Chromosomal Abnormalities in Refractory Anemia with Ringed Sideroblasts.. <i>Blood</i> , 2007 , 110, 4132-4132	2.2
193	Invariant Patterns of Clonal Succession Determines Specific Phenotypic and Clinical Features of Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2018 , 132, 104-104	2.2
192	TP53 Mutations in Myeloid Neoplasm Patients with and without Significant Personal and Family History of Cancer. <i>Blood</i> , 2018 , 132, 2270-2270	2.2
191	Molecular Characterization of Acute Myeloid Leukemia Patients with Normal Karyotype. <i>Blood</i> , 2018 , 132, 2809-2809	2.2
190	Distinct Features of Chip-Derived and De Novo MDS. <i>Blood</i> , 2018 , 132, 2572-2572	2.2

- 189 BRCA1 & BRCA2 Germline Variants Are Enriched in MDS/AML and Portend Higher Average Mutational Burden. *Blood*, **2018**, 132, 4352-4352 2.2
- 188 Does Trial Participation Improve Outcomes for Higher-Risk Myelodysplastic Syndromes (MDS) Patients Treated at Specialty Centers?. *Blood*, **2018**, 132, 3096-3096 2.2
- 187 Clinical and Molecular Heterogeneity of Moderate Aplastic Anemia. *Blood*, **2018**, 132, 2590-2590 2.2
- 186 Biallelic TET2 Inactivation in Myeloid Neoplasia: From Clonal Hierarchy to Clinical Phenotypes. *Blood*, **2018**, 132, 1805-1805 2.2
- 185 Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observational Study. *Blood*, **2018**, 132, 1388-1388 2.2
- 184 Pathogenic Germline Variants in Acquired Aplastic Anemia (AA) and Paroxysmal Nocturnal Hemoglobinuria (PNH). *Blood*, **2018**, 132, 2583-2583 2.2
- 183 Distinct Implications of TP53 Hits for Patients with Treatment-Related MDS and AML. *Blood*, **2018**, 132, 4353-4353 2.2
- 182 Opposing Pathogenesis of Germline SAMD9/SAMD9L Variants in Adult Myelodysplastic Syndrome (MDS). *Blood*, **2018**, 132, 4351-4351 2.2
- 181 Is There an Increased Risk of ALL in Patients with First Cancers Treated with Radiotherapy and/or Chemotherapy?. *Blood*, **2018**, 132, 900-900 2.2
- 180 Modulation of TET2 Activity By Ascorbic Acid and Factors Affecting Lysine Acetylation. *Blood*, **2018**, 132, 4346-4346 2.2
- 179 Molecular Spectrum of CSF3R variants Correlate with Specific Myeloid Malignancies and Secondary Mutations. *Blood*, **2018**, 132, 4389-4389 2.2
- 178 Evaluating the Evidence for Long-Term Benefit from Specialty Centers Versus Real World for MDS Patients Treated with HMA. *Blood*, **2018**, 132, 3095-3095 2.2
- 177 Association of MHC Class I Chain-Related Gene a (MICA) Polymorphisms with Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia. *Blood*, **2018**, 132, 2075-2075 2.2
- 176 Analysis of Even a Limited Number of Genes Indicates a Strong Inherited Component in Otherwise Typical Sporadic MDS. *Blood*, **2018**, 132, 3074-3074 2.2
- 175 Polyclonal Immune Response in T-LGL Leads to Clonal Expansions Preceding Occurrence of STAT3 Mutations Further Solidifying Clonal Dominance. *Blood*, **2018**, 132, 516-516 2.2
- 174 Disparities in Participation in Interventional Clinical Trials for Myelodysplastic Syndromes. *Blood*, **2018**, 132, 4374-4374 2.2
- 173 Survival Outcomes of Patients with Therapy-Related Acute Myeloid Leukemia in the United States. *Blood*, **2018**, 132, 2298-2298 2.2
- 172 Therapy-Related MDS Can be Separated into Different Risk-Groups According to Tools for Classification and Prognostication of Primary MDS. *Blood*, **2018**, 132, 3103-3103 2.2

171	Differences in Genomic Patterns between African Americans and Whites with Acute Myeloid Leukemia. <i>Blood</i> , 2018 , 132, 1527-1527	2.2
170	Survival Outcomes of Patients with Therapy-Related Myelodysplastic Syndromes in the United States. <i>Blood</i> , 2018 , 132, 371-371	2.2
169	Impact of Eltrombopag on Clonal Evolution in Refractory Aplastic Anemia. <i>Blood</i> , 2018 , 132, 3869-3869	2.2
168	Risk of Venous Thromboembolism in Acute Leukemias: A Meta-Analysis. <i>Blood</i> , 2018 , 132, 4805-4805	2.2
167	T-cell large granular lymphocytic leukemia evolution post-transplant: The Cleveland Clinic experience.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e19072-e19072	2.2
166	CUL1: Novel Therapeutic Target in Myeloid Neoplasms Harboring -7/Del(7q). <i>Blood</i> , 2019 , 134, 1281-1281.	2.2
165	Towards Molecularly Informed Acute Myeloid Leukemia Subtyping Reflective of Pathogenesis. <i>Blood</i> , 2019 , 134, 1406-1406	2.2
164	Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) in the Connect MDS/AML Registry. <i>Blood</i> , 2019 , 134, 4747-4747	2.2
163	Molecular Dissection of Del(5q): Distinction between Primary and Secondary Del(5q) and Pathogenetic Implications. <i>Blood</i> , 2019 , 134, 4221-4221	2.2
162	The Biological Inferences from the Ranking of SF3B1 Mutations in the Clonal Hierarchy of Myeloid Neoplasia. <i>Blood</i> , 2019 , 134, 5411-5411	2.2
161	Mutational Type and Configuration of an Individual Gene May Differentially Impact the Clinical and Phenotypic Features. <i>Blood</i> , 2019 , 134, 2992-2992	2.2
160	Molecular Characterization of Leukemia Evolving from Paroxysmal Nocturnal Hemoglobinuria. <i>Blood</i> , 2019 , 134, 2499-2499	2.2
159	Identifying Factors That Predict for Unplanned Readmissions for Acute Myeloid Leukemia Patients Receiving Consolidation Cytarabine Based Therapies. <i>Blood</i> , 2019 , 134, 3433-3433	2.2
158	Therapeutic Applications of a Unique Calcium Channel Blocker to Target SF3B1 MDS. <i>Blood</i> , 2019 , 134, 881-881	2.2
157	Pharmacologic Normalization of Altered Transcriptome of SF3B1 Mutant Myeloid Neoplasia. <i>Blood</i> , 2019 , 134, 564-564	2.2
156	Molecular Characterization of EP300 Mutant Myeloid Neoplasia. <i>Blood</i> , 2019 , 134, 5043-5043	2.2
155	TET2 Loss Accelerates Leukemogenesis By Disrupting Mismatch Repair Proteins. <i>Blood</i> , 2019 , 134, 1200-1200	2.2
154	Long-Term Experience with Large Granular Lymphocytic Leukemia Evolving after Solid Organ and Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2019 , 134, 1226-1226	2.2

- 153 ANKRD26 Coding Variants Presenting with Giant Platelets and a Predisposition to Myeloid Neoplasia. *Blood*, **2019**, 134, 4233-4233 2.2
- 152 Large Granular Lymphocytic Leukemia Coexists with Clonal Hematopoiesis of Indeterminate Potential. *Blood*, **2019**, 134, 3743-3743 2.2
- 151 Reversible TET Inhibitor As a Hematopoietic Stem Cell Booster: A Novel Strategy to Improve Stem Cell Function. *Blood*, **2019**, 134, 2472-2472 2.2
- 150 Predicting Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (MDS) Using Artificial Intelligence (AI). *Blood*, **2019**, 134, 2089-2089 2.2
- 149 Interactions between Donor Activating Killer Immunoglobulin-like Receptors (KIRs) and Somatic Mutations and Their Association with Outcomes after Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia (AML). *Blood*, **2019**, 134, 4599-4599 2.2
- 148 A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy. *Blood*, **2019**, 134, 2595-2595 2.2
- 147 Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study. *Blood*, **2019**, 134, 4271-4271 2.2
- 146 Determinants of "Fitness" for Intensive Therapy Among Acute Myeloid Leukemia (AML) Patients. *Blood*, **2019**, 134, 3836-3836 2.2
- 145 Integrated Analysis of Copy-Number Alterations and Gene Mutations in 2,000 Patients with Myeloid Neoplasms. *Blood*, **2019**, 134, 4216-4216 2.2
- 144 Clinical benefit of luspatercept in patients (pts) with lower-risk MDS (LR-MDS) and high transfusion burden in the phase III MEDALIST study.. *Journal of Clinical Oncology*, **2020**, 38, 7554-7554 2.2
- 143 Longer-term RBC transfusion reduction in the phase III MEDALIST study of luspatercept in patients (pts) with lower-risk MDS with ring sideroblasts (RS).. *Journal of Clinical Oncology*, **2020**, 38, 7518-7518 2.2
- 142 Mutation Profiling of Therapy-Related Myeloid Neoplasms Using Next-Generation Sequencing Demonstrates Distinct Profiles from De Novo Disease. *Blood*, **2014**, 124, 4611-4611 2.2
- 141 Analysis of Clonal Hierarchy Shows That Other Ancestral Events May Precede Evolution of Del(5q) in Myeloid Neoplasms. *Blood*, **2014**, 124, 4605-4605 2.2
- 140 Different Genomic Patterns in Patients with Primary Acute Myeloid Leukemia (AML) Compared to Secondary AML in Patients with Normal Karyotype. *Blood*, **2014**, 124, 1054-1054 2.2
- 139 Knowledge That the Myelodysplastic Syndromes (MDS) Are a Type of Cancer Does Not Influence Patient Perception of Treatment Discontinuation. *Blood*, **2014**, 124, 6015-6015 2.2
- 138 A Novel Prognostic Model in Heavily Treated Patients with Myelodysplastic Syndromes (MDS). *Blood*, **2014**, 124, 168-168 2.2
- 137 Long-Term Outcome of Patients with Myelodysplastic Syndromes (MDS) Treated with Hypomethylating Agents (HMA): A Report on Behalf of the MDS Clinical Research Consortium. *Blood*, **2014**, 124, 4641-4641 2.2
- 136 A Prognostic Scoring System for Newly Diagnosed Adult Acute Lymphocytic Leukemia Patients. *Blood*, **2014**, 124, 5252-5252 2.2

135	Chronic Myelomonocytic Leukemia (CMML) Can be Categorized By Ancestral Mutational Events. <i>Blood</i> , 2014 , 124, 1893-1893	2.2
134	Comparison of Very Low-Dose Decitabine to Standard-Dose Hypomethylating Agents in Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2014 , 124, 1933-1933	2.2
133	Relationship of Bone Marrow Blast (BMBL) Response to Overall Survival (OS) in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Treated with Rigosertib after Failure of Hypomethylating Agents (HMAs). <i>Blood</i> , 2014 , 124, 3259-3259	2.2
132	The Novel Plk Inhibitor Volasertib Overcomes Cytarabine Resistance in Acute Myeloid Leukemia. <i>Blood</i> , 2014 , 124, 979-979	2.2
131	The Efficacy of Current Prognostic Models in Predicting Outcome of Patients with Myelodysplastic Syndromes (MDS) at the Time of Hypomethylating Agent Failure. <i>Blood</i> , 2014 , 124, 3275-3275	2.2
130	Somatic Mutations of the Breast Cancer Amplified Sequence-1 (BCAS1), a Novel Leukemogenic Driver in Myelodysplastic Syndromes with Del(20q). <i>Blood</i> , 2014 , 124, 3250-3250	2.2
129	Nitric Oxide As a Mediator of Bone Marrow Fibrosis in Patients with Myelofibrosis. <i>Blood</i> , 2014 , 124, 4587-4587	2.2
128	Assessing the Value of Echocardiograms for Patients with Acute Myeloid Leukemia (AML) Receiving Anthracyclines. <i>Blood</i> , 2014 , 124, 1290-1290	2.2
127	Time to Complete Remission As a Function of Kinetics of White Blood Cell Elimination and Recovery in Acute Myeloid Leukemia Patients Undergoing Remission Induction Chemotherapy. <i>Blood</i> , 2014 , 124, 5266-5266	2.2
126	Impact and Function of Somatic PHF6 Mutations in Myeloid Neoplasms. <i>Blood</i> , 2014 , 124, 3581-3581	2.2
125	Distinct Pattern of Genomic Changes Associated with Hypoplastic Compared to Hyper/Normoblastic Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2014 , 124, 4603-4603	2.2
124	Inhibition of p97 with the First-in-Class Small Molecule CB-5083: A Novel Strategy for Acute Myeloid Leukemia Therapy. <i>Blood</i> , 2014 , 124, 3766-3766	2.2
123	Hereditary Mutations Are Present As Pathogenic or Predisposition Factors in Otherwise Typical Adult MDS. <i>Blood</i> , 2014 , 124, 3233-3233	2.2
122	Haploinsufficiency and Deletions of G3BP1 on Chromosome 5q Result in Induction of TP53. <i>Blood</i> , 2014 , 124, 784-784	2.2
121	Estimating Therapy-Related Myeloid Neoplasm Risks in the US. <i>Blood</i> , 2014 , 124, 2617-2617	2.2
120	Multiple Mechanisms Leading to ARID2 defects in Myeloid Neoplasms. <i>Blood</i> , 2014 , 124, 4610-4610	2.2
119	The Prognostic Utility of the Current Risk Models in Predicting Outcomes of Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Treated with Hypomethylating Agents (HMA). <i>Blood</i> , 2014 , 124, 1935-1935	2.2
118	Effect of Early Non-Hematologic Treatment Toxicity on Complete Remission (CR) and Time to CR in Acute Myeloid Leukemia Patients Undergoing Remission Induction Chemotherapy. <i>Blood</i> , 2014 , 124, 2279-2279	2.2

- 117 A multi-institution phase I trial of ruxolitinib in chronic myelomonocytic leukemia (CMML).. *Journal of Clinical Oncology*, **2015**, 33, 7021-7021 2.2
- 116 Impact of Hypomethylating Agent Therapy in Myelodysplastic Syndromes with Chromosome 3 Abnormalities. *Blood*, **2015**, 126, 1705-1705 2.2
- 115 Determinants of Phenotypic Commitment and Clonal Progression--Conclusions from the Study of Clonal Architecture in CMML. *Blood*, **2015**, 126, 2848-2848 2.2
- 114 Myelodysplastic Syndrome (MDS)-Determining Clonal Events at Presentation of Aplastic Anemia (AA). *Blood*, **2015**, 126, 1652-1652 2.2
- 113 Radioactive Iodine Treatment of Thyroid Cancer and Risk of Myelodysplastic Syndromes. *Blood*, **2015**, 126, 612-612 2.2
- 112 Conditional Survival in Patients with Del(5q) Myelodysplastic Syndromes Treated with Lenalidomide. *Blood*, **2015**, 126, 2867-2867 2.2
- 111 Real World Outcomes of Less Well-Characterized Acute Leukemias: A Population-Based Survival Analysis Using SEER Registry (1973-2012). *Blood*, **2015**, 126, 4491-4491 2.2
- 110 Predicting MDS Response to Drug Therapies Based on a New Method of Interpreting the MDS Mutanome. *Blood*, **2015**, 126, 96-96 2.2
- 109 Eligibility Criteria Are Not Associated with Expected or Observed Adverse Events in Randomized Controlled Trials (RCTs) of Hematologic Malignancies. *Blood*, **2015**, 126, 635-635 2.2
- 108 Characterization of the Mutational Spectrum in Young Patients with Myelodysplastic Syndrome. *Blood*, **2015**, 126, 5218-5218 2.2
- 107 The Complexity of Interpreting Genomic Data in Patients with Primary and Secondary Acute Myeloid Leukemia (AML). *Blood*, **2015**, 126, 86-86 2.2
- 106 Long-Term Follow-up Results: A Phase 2 Trial of Imatinib Mesylate As Maintenance Therapy for Patients with Newly Diagnosed c-Kit Positive Acute Myeloid Leukemia (AML). *Blood*, **2015**, 126, 2536-2536^{2.2}
- 105 North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute Leukemia. *Blood*, **2015**, 126, 1138-1138 2.2
- 104 A Novel Model to Predict Outcome of Patients with Myelodysplastic Syndromes (MDS) at the Time of Hypomethylating Agent Failure. *Blood*, **2015**, 126, 2888-2888 2.2
- 103 Network-Based Analysis of Exome Sequencing Mutations Identifies Molecular Subtypes of Myelodysplastic Syndromes. *Blood*, **2015**, 126, 611-611 2.2
- 102 Evolving Risk of Myelodysplastic Syndromes Among Adolescents and Young Adults Following Radiation Treatment for First Cancers in the United States, 1973 - 2014. *Blood*, **2016**, 128, 4334-4334 2.2
- 101 Evaluation of Salvage Induction Chemotherapy Regimens in Higher Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia after Hypomethylating Agent Treatment Failure. *Blood*, **2016**, 128, 348-348^{2.2}
- 100 Germline Variants of RUNX-1 in Myeloid Malignancy. *Blood*, **2016**, 128, 3926-3926 2.2

99	Clinical and Biological Implications of CUX1 Mutations in Myeloid Neoplasms. <i>Blood</i> , 2016 , 128, 3156-3156	2.2
98	A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib (MLN9708) for Relapsed/ Refractory Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016 , 128, 4065-4065	2.2
97	UTX mutations in Myeloid Neoplasms. <i>Blood</i> , 2016 , 128, 3148-3148	2.2
96	Distinct Clinical and Biological Implications of Various DNTMT3A Mutations in Myeloid Neoplasms. <i>Blood</i> , 2016 , 128, 2872-2872	2.2
95	Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes (MDS): Are They Two Faces of the Same Coin? a Study on Behalf of the MDS Clinical Research Consortium (MDS CRC). <i>Blood</i> , 2016 , 128, 4321-4321	2.2
94	Molecular and Clinical Characterization of Patients with Myeloid Neoplasms Carrying the 12p Deletion. <i>Blood</i> , 2016 , 128, 2007-2007	2.2
93	Phenotype/Genotype Associations in TET2-Driven Myeloid Neoplasms. <i>Blood</i> , 2016 , 128, 4313-4313	2.2
92	BCOR and BCORL1 mutations in Myelodysplastic Syndromes (MDS): Clonal Architecture and Impact on Outcomes. <i>Blood</i> , 2016 , 128, 4293-4293	2.2
91	Romiplostim in Thrombocytopenic Patients with Low- or Int-1- Risk MDS Results in Reduced Bleeding without Impacting Leukemic Progression: Final Follow-up Results from a Randomized, Double-Blind, Placebo-Controlled Study. <i>Blood</i> , 2016 , 128, 2000-2000	2.2
90	Prognostic Parameters in Adults with Acute Lymphoblastic Leukemia at Second Complete Response. <i>Blood</i> , 2016 , 128, 1603-1603	2.2
89	Rationale for Therapy Discontinuation in Patients with Lower-Risk Transfusion-Dependent Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2016 , 128, 3541-3541	2.2
88	Using Machine Intelligence Algorithms to Develop a Geno-Clinical Model to Predict Responses to Hypomethylating Agents in Myelodysplastic Syndromes. <i>Blood</i> , 2016 , 128, 3193-3193	2.2
87	Comparable Outcomes of Patients Eligible Versus Ineligible for Southwest Oncology Group (SWOG) Leukemia Studies. <i>Blood</i> , 2016 , 128, 4002-4002	2.2
86	the Impact of Clonal Dynamics on Prognosis and Outcome in Myelodysplastic Syndromes. <i>Blood</i> , 2016 , 128, 4287-4287	2.2
85	Landscape of Subclonal Mutations in Myelodysplastic Syndromes (MDS) Allows for a Novel Hierarchy of Clonal Advantage By Combining Germline and Somatic Mutations. <i>Blood</i> , 2016 , 128, 957-957	2.2
84	Next-Generation Sequencing Analysis of Clonal Hierarchy and Dynamics in T-Large Granular Lymphocyte Leukemia Suggests Emergence of STAT3 Clones within Pre-Existing Dominant T-Cell Repertoire Responses Otherwise Silenced in Normal Individuals. <i>Blood</i> , 2016 , 128, 2731-2731	2.2
83	FISH and SNP-Array Karyotyping Improve the Detection of Recurrent Chromosomal Defects Including Del(5q), Monosomy 7, Del(7q), Trisomy 8, and Del(20q) in Myelodysplastic Syndromes.. <i>Blood</i> , 2008 , 112, 1483-1483	2.2
82	OCT-2 Expression and OCT-2/BOB.1 Co-Expression Predict Prognosis in Patients with Newly Diagnosed Acute Myelogenous Leukemia.. <i>Blood</i> , 2008 , 112, 1486-1486	2.2

- 81 Histone H4 Acetylation as a Prognostic Factor for Patients with Acute Lymphocytic Leukemia in First Relapse.. *Blood*, **2008**, 112, 1482-1482 2.2
- 80 Acquired 1p Uniparental Disomy Is Associated with Biallelic MPL W515L Mutation in RARS-T.. *Blood*, **2008**, 112, 1643-1643 2.2
- 79 Minimizing Therapy for Patients with Acute Promyelocytic Leukemia: Efficacy of Single Cycle of Arsenic-Based Consolidation Therapy.. *Blood*, **2008**, 112, 1932-1932 2.2
- 78 A Phase 1 Trial of Imatinib Mesylate with Daunorubicin and Cytarabine for Patients with C-Kit Positive Relapsed AML.. *Blood*, **2008**, 112, 955-955 2.2
- 77 Impact of Weekend Admissions on Quality of Care and Outcomes in Patients with Acute Myeloid Leukemia (AML).. *Blood*, **2008**, 112, 1942-1942 2.2
- 76 SNP-Array Based Karyotyping Complements Routine Cytogenetics in Diagnosis and Risk Stratification Schemes of MDS. *Blood*, **2008**, 112, 639-639 2.2
- 75 Array-Based Karyotyping and Genotyping Demonstrates a Non Random Selection of Allelic Variants of Genes in Clones with 5q31 Deletion Mutants.. *Blood*, **2008**, 112, 2057-2057 2.2
- 74 TET2 Mutations Are Frequent in RARS-T.. *Blood*, **2009**, 114, 3794-3794 2.2
- 73 The Value of Post-Remission Therapy in Older Adults with Acute Myeloid Leukemia (AML).. *Blood*, **2009**, 114, 1043-1043 2.2
- 72 Molecular Lesions Associated with Loss of Heterozygosity Identified in CMML.. *Blood*, **2009**, 114, 416-416 2.2
- 71 Acquired Somatic Uniparental Disomy is a Chromosomal Defect Important in Predicting Treatment Responses and Survival Outcomes in MDS, MDS/MPN and Secondary AML.. *Blood*, **2009**, 114, 2630-2630 2.2
- 70 Strong Histone (H4) Acetylation Is Independently Associated with Better Overall Survival in Newly Diagnosed Acute Myeloid Leukemia (AML).. *Blood*, **2009**, 114, 4681-4681 2.2
- 69 Whole Epigenome Pattern Characterization in CMML and Related Monocytoid Malignancies.. *Blood*, **2009**, 114, 599-599 2.2
- 68 New TET2, ASXL1 and CBL Mutations Have Poor Prognostic Impact In Systemic Mastocytosis and Related Disorders. *Blood*, **2010**, 116, 3076-3076 2.2
- 67 Duration of Antecedent Complete Blood Cell Count (CBC) Abnormalities Predicts Response and Survival Rates In De Novo and Secondary AML.. *Blood*, **2010**, 116, 1040-1040 2.2
- 66 SNP-A Karyotyping Provides Clinically Relevant Results In Myeloid Hematologic Disorders with Unsuccessful Routine Cytogenetic Testing.. *Blood*, **2010**, 116, 3374-3374 2.2
- 65 A High Resolution Analysis of Chromosome 21 Amplification In Myeloid Malignancies Reveals An Association with a Specific Cytogenetic Subgroup and Enhanced ERG Gene Expression.. *Blood*, **2010**, 116, 1687-1687 2.2
- 64 Identification of Oncogenic EZH2 Mutations In Myelodysplastic Syndromes and Related Myeloid Malignancies. *Blood*, **2010**, 116, 607-607 2.2

- 63 Effective and Non-Cytotoxic p53 Independent Epigenetic-Differentiation Therapy In Xeno-Transplant Models of Human Acute Myeloid Leukemia. *Blood*, **2010**, 116, 3309-3309 2.2
- 62 Cigarette Smoking Is Associated with Increased Rates of Fungal Infection and Increased Mortality After Allogeneic Transplantation. *Blood*, **2010**, 116, 2321-2321 2.2
- 61 Predictors of Outcome In Patients with Myelodysplastic Syndromes Living In Western Pennsylvania. *Blood*, **2010**, 116, 4971-4971 2.2
- 60 A Retrospective Multi-Center Analysis of Prognostic Factors Determining Outcomes In Patients with Secondary AML. *Blood*, **2010**, 116, 2139-2139 2.2
- 59 Various Abnormalities at Chromosome 7 Carry Distinct Biologic and Prognostic Implications In Myelodysplastic/Myeloproliferative Syndromes and Related Marrow Failures. *Blood*, **2010**, 116, 2744-2744² 2.2
- 58 Expression of Phosphorylated Signal Transducer and Activator of Transcription 5 (pSTAT5) Is Associated with An Increased Risk of Death In Acute Myeloid Leukemia.. *Blood*, **2010**, 116, 1675-1675 2.2
- 57 Prognostic Significance of Histone (H4) Acetylation In Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with Intermediate Risk Cytogenetics. *Blood*, **2010**, 116, 2736-2736 2.2
- 56 Mechanisms of Defective Hydroxylation of 5-Methylcytosine in MDS Include Pathways Other Than TET2 and IDH1/2. *Blood*, **2011**, 118, 462-462 2.2
- 55 Phase 1 Dose-Ranging Study of Oral Ezatiostat Hydrochloride (Telintra[®], TLK199) in Combination with Lenalidomide (Revlimid[®]) in Patients with Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS). *Blood*, **2011**, 118, 2778-2778 2.2
- 54 Spliceosome GENE MUTATIONS ARE Also PRESENT In the Diverse Mutational Spectrum of CHRONIC Myelomonocytic LEUKEMIA. *Blood*, **2011**, 118, 1402-1402 2.2
- 53 Response to High Dose Cytarabine (HIDAC) As First Salvage for Relapsed Acute Lymphocytic Leukemia in Patients Receiving HIDAC As Initial Therapy. *Blood*, **2011**, 118, 2594-2594 2.2
- 52 Defining the Topography of Deletion 5q Using SNP-A Identifies Patients with More Aggressive Disease and Correlates with Additional Lesions. *Blood*, **2011**, 118, 2795-2795 2.2
- 51 Radiation Treatment for Localized Prostate Cancer and the Risk of Developing Myelodysplastic Syndromes (MDS). *Blood*, **2011**, 118, 120-120 2.2
- 50 EZH2 Is Either Mutated or Downregulated in Patients with Loss of Heterozygosity of Chromosome 7/7q and Leads to Epigenetic Dysregulation Via Histone H3K27.. *Blood*, **2011**, 118, 228-228 2.2
- 49 Absolute Lymphocyte Count At Day 28 Independently Predicts Event-Free and Overall Survival in Adults with Newly Diagnosed Acute Lymphocytic Leukemia. *Blood*, **2011**, 118, 2552-2552 2.2
- 48 Prognostic Factors of Response and Survival in CMML Patients Treated with Azacitidine (AZA). *Blood*, **2011**, 118, 1726-1726 2.2
- 47 Acquired Molecular Defects in Spliceosome Machinery: Novel Pathogenetic Pathways in Myeloid Leukemogenesis. *Blood*, **2011**, 118, 271-271 2.2
- 46 Prognostic Factors for Post-Transplant Outcomes in Patients with Myelodysplastic Syndromes (MDS). *Blood*, **2011**, 118, 2015-2015 2.2

- 45 A Proof of Principle Clinical Trial in Myelodysplastic Syndromes of Non-Cytotoxic Differentiation Therapy with Decitabine. *Blood*, **2011**, 118, 3830-3830 2.2
- 44 Outcomes in Obese and Overweight Acute Myeloid Leukemia (AML) Patients Receiving Chemotherapy Dosed According to Actual Body Weight. *Blood*, **2011**, 118, 1496-1496 2.2
- 43 Gender Is A Major Determinant of Cytidine Analogue Metabolism and May Contribute to Differences in Treatment Outcomes. *Blood*, **2011**, 118, 1434-1434 2.2
- 42 Distinction of Early and Late Molecular Events In Patients with Myelodysplastic Syndromes (MDS) Who Progressed to Acute Myeloid Leukemia (AML). *Blood*, **2011**, 118, 3566-3566 2.2
- 41 The Impact of Molecular Lesions in Post-Transplant Acute Myeloid Leukemia (AML) in Correlation with Cytogenetic Abnormalities. *Blood*, **2011**, 118, 4137-4137 2.2
- 40 Identifying Immunogenetic Features That Distinguish Immune Mediated, Immunosuppression-Sensitive Disease in Aplastic Anemia (AA). *Blood*, **2012**, 120, 3481-3481 2.2
- 39 Molecular Diversity Detected by Whole Exome Sequencing in Chronic Myelomonocytic Leukemia. *Blood*, **2012**, 120, 310-310 2.2
- 38 Racial Differences in Prognostic Factors and Outcomes in Patients Undergoing Allogeneic Hematopoietic Cell Transplant. *Blood*, **2012**, 120, 2020-2020 2.2
- 37 A Prognostic Scoring System for Unclassifiable MDS and MDS/MPN. *Blood*, **2012**, 120, 1701-1701 2.2
- 36 Impact of Myocardial Infarction On Survival in Acute Myeloid Leukemia. *Blood*, **2012**, 120, 4321-4321 2.2
- 35 Disparity in Perceptions of Disease, Treatment Effectiveness and Treatment Adherence Between Physicians and Patients with Myelodysplastic Syndromes (MDS). *Blood*, **2012**, 120, 4949-4949 2.2
- 34 Role of p38 MAPK and Tie2 in the Pathogenesis of MDS and Their Inhibition by Dual Inhibitor ARRY-614. *Blood*, **2012**, 120, 2825-2825 2.2
- 33 Pathway Analysis of Molecular Mutations Can Modify Morphologic, Cytogenetic and Prognostic Risk Stratification Schemes in Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes/Myeloproliferative Neoplasms (MDS/MPN), and Secondary Acute Myeloid Leukemia (AML). *Blood*, **2012**, 120, 3791-3791 2.2
- 32 Mutational Spectrum of Myelodysplastic Syndrome Malignancies Revealed by Whole Exome Sequencing. *Blood*, **2012**, 120, 307-307 2.2
- 31 Anemia Associated with Increased IL-6 and IL-8 Levels Predicts for Worse Progression-Free Survival in T-Cell and NK-Cell Large Granular Lymphocyte (LGL) Leukemia but Is Improved by Treatment with Cyclophosphamide. *Blood*, **2012**, 120, 1261-1261 2.2
- 30 A Phase 2 Trial of Imatinib Mesylate As Maintenance Therapy for Patients with Newly Diagnosed C-Kit Positive Acute Myeloid Leukemia (AML). *Blood*, **2012**, 120, 3597-3597 2.2
- 29 SF3B1, a Splicing Factor Gene, Is Infrequently Mutated in Rare Bone Marrow Failure Diseases but Still Associated with Ring Sideroblast Phenotype. *Blood*, **2012**, 120, 3485-3485 2.2
- 28 Biological Rationale for the Favorable Clinical Outcomes of Patients Carrying SF3B1 Mutations in Myelodysplastic Syndromes with Ring Sideroblasts. *Blood*, **2012**, 120, 922-922 2.2

27	Newly Acquired Molecular Mutations and SNP-A Lesions Alters the Natural History of Trisomy 8 Myeloid Neoplasms. <i>Blood</i> , 2012 , 120, 312-312	2.2
26	Predictive Factors for Latency Period and a Prognostic Model for Survival in Patients with Therapy-Related AML. <i>Blood</i> , 2012 , 120, 2589-2589	2.2
25	Molecular Mutations in U2AF1 Are Most Commonly Found in Del20q Myelodysplastic Syndromes but Do Not Lead to Poor Prognosis in This Karyotypic Subtype. <i>Blood</i> , 2012 , 120, 3804-3804	2.2
24	Patients with SF3B1 Mutation Have Good Prognosis Even in the Presence of Other Poor Prognostic MDS Features and Have Better Outcomes During Treatment with Low Intensity Chemotherapy. <i>Blood</i> , 2012 , 120, 3831-3831	2.2
23	Novel Recurrent Mutations in the Ras-Like GTP-Binding Gene Rit1 in Myeloid Malignancies. <i>Blood</i> , 2012 , 120, 558-558	2.2
22	Central Line-Associated Blood Stream Infections Following Hematopoietic Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Incidence, Risk Factors, and Impact On Survival. <i>Blood</i> , 2012 , 120, 4481-4481	2.2
21	Clinical and Molecular Features Of Young Patients With Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2013 , 122, 1566-1566	2.2
20	Comprehensive Identification Of Germline Alterations In Telomerase Complex Genes By Whole Exome Sequencing Of MDS and Related Myeloid Neoplasms. <i>Blood</i> , 2013 , 122, 522-522	2.2
19	Prospective Study Of An Emergency Department Febrile Neutropenia Pathway In Patients With Hematologic Malignancies. <i>Blood</i> , 2013 , 122, 556-556	2.2
18	Somatic Mutations and Loss-Of-Heterozygosity Impair The DNA Repair Functions Of CUX1 in Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2013 , 122, 1246-1246	2.2
17	Spliceosome Mutations Are Frequent In Patients With Myelodysplastic Syndromes Who Failed Hypomethylating Therapy: Possible Implications Of Spliceosome Inhibitors As Alternative Treatments. <i>Blood</i> , 2013 , 122, 5237-5237	2.2
16	Molecular Predictors Of Response To Lenalidomide In Myeloid Malignancies. <i>Blood</i> , 2013 , 122, 2807-2807	2.2
15	Poor Survival Outcomes In Myelodysplastic Syndrome Patients With Non-t(6;9) and Non-Inv(3) Balanced Chromosomal Rearrangements Are Influenced By SRSF2 Mutations. <i>Blood</i> , 2013 , 122, 2809-2809	2.2
14	Whole Exome Sequencing (Mutatome) Of Deletion 5q. <i>Blood</i> , 2013 , 122, 656-656	2.2
13	Differences In Perceptions Of Disease and Treatment Effectiveness and Adherence Between Physicians and Patients With Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2013 , 122, 724-724	2.2
12	Risk Of Acute and Chronic Leukemias Following Radiation Treatment For Locoregional Prostate Cancer In The United States Over 35-Years. <i>Blood</i> , 2013 , 122, 2652-2652	2.2
11	The Revised International Prognostic Scoring System (IPSS-R) Is Not Predictive Of Survival In Patients With Secondary Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2013 , 122, 1524-1524	2.2
10	Spliceosome Gene Mutations Are Frequently Found In JAK2 Negative Myelofibrosis and Associated With Worse Clinical Outcomes. <i>Blood</i> , 2013 , 122, 4063-4063	2.2

9	Impact Of The Proportion Of Metaphases With Isolated Del(5q) On Clinical Outcomes In Lenalidomide (LEN)-Treated Patients With IPSS Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) In MDS-003 and MDS-004. <i>Blood</i> , 2013 , 122, 1538-1538	2.2
8	Triple Negative (JAK2 exon 12 /14 and MPL wild type) Myelofibrosis Have Higher Expression Of CDC25A and Greater Sensitivity To CDC25A Inhibition Compared To JAK2 Mutant Cases. <i>Blood</i> , 2013 , 122, 5259-5259	2.2
7	Eat and be healthy: nutritional status in myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2788-2789	1.9
6	Myelodysplastic/myeloproliferative neoplasm overlap syndromes 120-128	
5	Myelodysplastic Syndromes: Going Gently Into That Good Night. <i>Journal of Oncology Practice</i> , 2016 , 12, 795-6	3.1
4	Myelodysplastic Syndromes (MDS) 2019 , 333-341	
3	Descriptive comparison of hospital formulary decisions with published oncology valuation methods. <i>Journal of Oncology Pharmacy Practice</i> , 2020 , 26, 891-905	1.7
2	The role of hypomethylating agents prior to hematopoietic cell transplantation in myelodysplastic syndromes. <i>Best Practice and Research in Clinical Haematology</i> , 2018 , 31, 346-350	4.2
1	The Transplant. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3185-3187	2.2